US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028

July 2023 | 3600 pages | ID: U807F8C7DEABEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028 Report Highlights:

• US Orphan Drugs Market Opportunity: > USD 150 Billion By 2028
• Orphan Drugs Dosage, Price & Treatment Cost: > 350 Orphan Drug
• Annual & Quarterly Sales Insight (2019 – Q1’2023):> 100 Orphan Drugs
• US Orphan Drugs Reimbursement Scenario: Medicare, Medicaid, Private Insurers
• Active Clinical Trials Insight By Company, Indication & Phase: 1000 Orphan Drugs
• Marketed Orphan Drugs Clinical Insight By Company & Indication: > 400 Orphan Drugs
• Competitive Landscape: 75 Companies

Considering the increasing burden of patients suffering from rare and orphan diseases, the US FDA has taken several steps to increase the interest of the research and pharmaceutical companies to these forgotten diseases. One of the fundamental actions taken by the FDA is the assignment of the orphan drug designation, which gives developers benefits in the course of the research and development, clinical assessment and marketing of the drug. The orphan drug designation has been granted to over 6500 drugs and compounds, and around 100 of these have received regulatory approvals. Therefore, though the number is less, these drugs have been essential for improving the treatment outcomes of patients suffering from rare orphan diseases. Taking into account the continued success of several drugs in the US pharmaceutical market, it is evident these therapeutic products are faring well in spite of the small patient base, which makes it an interesting domain to explore.

Earlier rare diseases were neglected due to low profitability feasibility, but enactment of FDA’s Orphan Drug Act 1983, succeeding regulatory reforms, government funding support and extensive research by pharmaceutical companies led to exponential growth in the US orphan drugs market. These favorable parameters resulted in more than 1000 orphan designated drugs in clinical trials and more than 400 orphan designated drugs being commercially available in the market. This number is further expected to surpass 500 orphan designated drugs in market by 2028 driven by increasing focus of pharmaceutical companies on rare diseases. The US orphan drugs market was valued around US$ 100 Billion in 2022, and is further expected to surpass US$ 180 Billion by 2028, making it one of the highest revenue-generating segments of the global orphan-designated drugs market.

Many drugs that were given the orphan designation for rare indications have already gained US FDA approval for a different, non-orphan indication. Observation studies, anecdotal evidence, or unexpected clinical results from clinical trials involving patients with unrelated indications are what lead researchers to the conclusion that the same drug may also be utilized for a rare indication. As a result, it frequently happens that pharmaceutical companies are unaware of the potential of their products as therapeutic treatments for rare diseases. On the plus side, completing clinical trials for uncommon diseases, and subsequently being given the orphan drug designation, can aid in growing the patient base for the company and the drug, which will later boost revenues.

Contents

1. US ORPHAN DRUGS MARKET OVERVIEW

1.1 FDA Designation Criteria & Market Exclusivity
1.2 Current Market Scenario
1.3 Future Market Trends & Opportunity Assessment

2. PARTNERSHIPS & COLLABORATIONS CONCERNING ORPHAN DRUGS

3. US ORPHAN DRUGS MARKET TRENDS BY INDICATION

3.1 Cancer
3.2 Neurological Disorders
3.3 Cardiovascular Disorders
3.4 Ophthalmic Diseases
3.5 Rare Genetic Disorders & Metabolic Disorders
3.6 Autoimmune & Inflammatory Diseases

4. US ORPHAN DRUGS REIMBURSEMENT SCENARIO

4.1 Medicare
4.2 Medicaid
4.3 Private Insurers
4.4 Pharmaceutical Companies

5. US ORPHAN DESIGNATED DRUGS DOSAGE, PRICE & TREATMENT COST INSIGHT

This Chapter Gives Comprehensive Insights On 375 Orphan Drugs. For Representation Purpose We Have Mentioned Few Drugs Name In Table Of Content. Detailed List Is Provided In Report Sample.
5.1 Lynparza
5.2 Nplate
5.3 Tafinlar
5.4 Halaven
5.5 Jadenu
5.6 Xpovio
5.7 Gavreto
5.8 Ocaliva
5.9 INOmax
5.10 Truseltiq
5.11 Lumakras
5.12 Monjuvi
5.13 Onpattro
5.14 Opdivo
5.15 Opdualag
5.370 Colazal (Balsalazide Disodium)
5.371 Anascorp (Centruroides (Scorpion) Immune F(ab’)2 (Equine) Injection)
5.372 Nithiodote (sodium nitrite and sodium thiosulfate)
5.373 BabyBIG (Botulism Immune Globulin Intravenous [Human])
5.374 NexoBrid (anacaulase-bcdb)
5.375 Sarclisa (Isatuximab)

6. US ORPHAN DESIGNATED DRUGS SALES INSIGHT (2019 – Q1’2023)

This Chapter Gives Comprehensive Insights On 106 Orphan Drugs. For Representation Purpose We Have Mentioned Few Drugs Name In Table Of Content. Detailed List Is Provided In Report Sample.
6.1 Tafinlar
6.2 Jadenu
6.3 Zolgensma
6.4 Lynparza
6.5 Nplate
6.6 Lumakras
6.7 Repatha
6.8 Otezla
6.9 Kyprolis
6.10 Opdivo
6.11 Opdualag
6.12 Empliciti
6.13 Braftovi
6.14 Mektovi
6.15 Lorbrena
6.100 Praluent
6.101 Mozobil
6.102 Yescarta
6.103 Lunsumio
6.104 Keytruda
6.105 Pemazyre
6.106 Camzyos

7. US ORPHAN DESIGNATED DRUGS CLINICAL TRIALS INSIGHT

7.1 By Company
7.2 By Indication
7.3 By Patient Segment
7.4 By Phase
7.5 By Priority Status

8. US ORPHAN DRUGS CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
8.9 Registered

9. MARKETED ORPHAN DRUGS CLINICAL INSIGHT BY COMPANY & INDICATION

10. COMPETITIVE LANDSCAPE

10.1 AbbVie
10.2 Alexion (AstraZeneca Rare Disease Group)
10.3 Alnylam Pharmaceuticals
10.4 Amgen
10.5 Amicus Therapeutics
10.6 Array BioPharma
10.7 Astellas Pharma
10.8 AstraZeneca
10.9 Bayer HealthCare
10.10 Beacon Therapeutics
10.11 BioMarin Pharmaceutical
10.12 Bioverativ
10.13 Boehringer Ingelheim
10.14 Bristol-Myers Squibb
10.15 Celgene Corporation
10.16 Chiesi
10.17 Chugai Pharmaceutical
10.18 Collaborations Pharmaceuticals
10.19 CSL
10.20 Daiichi Sankyo Company
10.21 Eisai Co Ltd
10.22 Eli Lilly & Company
10.23 Emergent BioSolutions
10.24 Ferring Pharmaceuticals
10.25 Fred Hutchinson Cancer Research Center
10.26 Flavocure Biotech
10.27 Genentech
10.28 Genmab
10.29 Gilead Sciences
10.30 GlaxoSmithKline
10.31 GSK
10.32 Hanmi Pharmaceutical
10.33 Horizon Therapeutics plc
10.34 Incyte Corporation
10.35 Ionis Pharmaceuticals
10.36 Ipsen
10.37 Janssen Biotech
10.38 Jazz Pharmaceuticals plc
10.39 Johnson & Johnson
10.40 Kamada
10.41 Krystal Biotech
10.42 Kyowa Kirin
10.43 Leadiant Biosciences
10.44 Ligand Pharmaceuticals
10.45 Lundbeck A/S
10.46 MeiraGTx
10.47 Memorial Sloan-Kettering Cancer Center
10.48 Merck
10.49 Moderna Therapeutics
10.50 Nationwide Children's Hospital
10.51 Nonindustrial Source
10.52 Novartis
10.53 Novo Nordisk
10.54 Omeros Corporation
10.55 Onyx Pharmaceuticals (Amgen)
10.56 Otsuka Pharmaceutical
10.57 Pfizer
10.58 PTC Therapeutics
10.59 Recordati
10.60 Regeneron Pharmaceuticals
10.61 Roche
10.62 Sanofi
10.63 Servier
10.64 Shionogi
10.65 Spark Therapeutics
10.66 Sumitomo Pharma
10.67 Sutro Biopharma
10.68 Swedish Orphan Biovitrum
10.69 Takeda
10.70 Teva Pharmaceutical Industries
10.71 UCB
10.72 UniQure
10.73 Vertex Pharmaceuticals
10.74 XOMA
10.75 ZymoGenetics (BMS)

List Of Figures

LIST OF FIGURES

Figure 1-1: US – Orphan Drugs Market Size (US$ Billion), 2022 - 2028
Figure 3-1: TP-1287 – Study Initiation & Completion Year
Figure 3-2: ATG-022 – Study Initiation & Completion Year
Figure 3-3: ATG-101: Study Initiation & Completion Year
Figure 3-4: Lacutamab – Study Initiation & Completion Year
Figure 3-5: CART-ddBCMA – Study Initiation & Completion Year
Figure 3-6: FORE8394 – Study Initiation & Completion Year
Figure 3-7: ERAS-801 – Study Initiation & Completion Year
Figure 3-8: Tirabrutinib – Study Initiation & Completion Year
Figure 3-9: Temferon - Study Initiation & Completion Year
Figure 3-10: RP-A601 - Study Initiation & Completion Year
Figure 3-11: RP-A501 – Study Initiation & Completion Year
Figure 3-12: HG004 – Study Initiation & Completion Year
Figure 3-13: EA-2353 – Study Initiation & Completion Year
Figure 3-14: ARD-101 – Study Initiation & Completion Year
Figure 3-15: SYNB1934 – Study Initiation & Completion Year
Figure 3-16: ST-920 – Study Initiation & Completion Year
Figure 5-1: US – Lynparza Approvals by Indication
Figure 5-2: US – Lynparza Orphan Drug Designation Years by Indication
Figure 5-3: US – Cost of 60 & 120 Tablets Supply of 100 mg & 150 mg Lynparza (US$), July’2023
Figure 5-4: US – Monthly Cost of Treatment with 100 mg & 150 mg Lynparza Tablets (US$), July’2023
Figure 5-5: US – Cost of 125 mcg, 250 mcg & 500 mcg Supply Packs of Nplate (US$), July’2023
Figure 5-6: US – Tafinlar Approvals by Indication
Figure 5-7: US – Tafinlar Orphan Drug Designation Years
Figure 5-8: US – Cost of Per Unit & Supply of 120 Capsules of 50mg & 75mg Tafinlar (US$), July’2023
Figure 5-9: US – Monthly Cost of Tafinlar Treatment by Weight (US$), July’2023
Figure 5-10: US – Halaven Approvals by Indication
Figure 5-11: US – Monthly Cost of Treatment with Havalen Injection (US$), July’2023
Figure 5-12: US – Jadenu Orphan Drug Designation Years by Indication
Figure 5-13: US – Cost of Per Unit & Supply of 30 Tablets of 90mg, 180mg & 360mg Jadenu (US$), July’2023
Figure 5-14: US – Monthly Cost of Treatment with Jadenu (US$), July’2023
Figure 5-15: US – Xpovio Orphan Drug Designation & Approval Years by Indication
Figure 5-16: US – Cost of Per Unit & Supply of 20mg Xpovio Tablets (US$), July’2023
Figure 5-17: US – Cost of Per Unit & Supply of 40mg Xpovio Tablets (US$), July’2023
Figure 5-18: US – Cost of Per Unit & Supply of 50mg & 60mg Xpovio Tablets (US$), July’2023
Figure 5-19: US – Monthly Cost of Treatment with Xpovio (US$), July’2023
Figure 5-20: US – Gavreto Orphan Drug Designation & Approval Years by Indication
Figure 5-21: US – Cost of Per Unit & Supply of 100mg Gavreto Tablets (US$), July’2023
Figure 5-22: US – Monthly Cost of Treatment with Gavreto Capsule (US$), July’2023
Figure 5-23: US – Cost of Per Unit & Supply of 5mg & 10mg Ocaliva Tablets (US$), July’2023
Figure 5-24: US – INOmax Orphan Drug Designation & Approval Years
Figure 5-25: US – Truseltiq Orphan Drug Designation & Approval Years
Figure 5-26: US – Cost of Per Unit & Supply of Different Truseltiq Doses (US$), July’2023
Figure 5-27: US – Monthly & Yearly Cost of Treatment with Truseltiq (US$), July’2023
Figure 5-28: US – Lumakras Orphan Drug Designation & Approval Years
Figure 5-29: US – Cost of Per Unit & Supply of 120mg & 320mg Lumakras Doses (US$), July’2023
Figure 5-30: US – Monjuvi Orphan Drug Designation & Approval Years by Indication
Figure 5-31: US – Cost of Truseltiq Treatment Cycles US$), July’2023
Figure 5-32: US – Onpattro Orphan Drug Designation & Approval Years
Figure 5-33: US – Cost of Per Unit & Supply of 5mL Vial of Onpattro (US$), July’2023
Figure 5-34: US – Cost of Onpattro Treatment by Weight US$), July’2023
Figure 5-35: US – Cost of Per Unit & Supply of 10 mg/mL Opdivo (US$), July’2023
Figure 5-36: US – Opdualag Orphan Drug Designation & Approval Years
Figure 5-37: US – Cost of Per Unit & Supply of Opdualag Solution (US$), July’2023
Figure 5-38: US – Unit, Monthly & Yearly Cost of Opdualag Treatment US$), July’2023
Figure 5-39: US – Orladeyo Orphan Drug Designation & Approval Years
Figure 5-40: US – Cost of Per Unit & Supply of Orladeyo Capsule (US$), July’2023
Figure 5-41: US – Orladeyo Orphan Drug Designation & Approval Years
Figure 5-42: US – Cost of Per Unit & Supply of Rubraca Tablet (US$), July’2023
Figure 5-43: US – Livmarli Orphan Drug Designation & Approval Years
Figure 5-44: US – Cost of Per Unit & Supply of Livmarli Solution (US$), July’2023
Figure 5-45: US – Unit, Monthly & Yearly Cost of Livmarli Treatment US$), July’2023
Figure 5-46: US – Bendeka Orphan Drug Designation & Approval Years
Figure 5-47: US – Cost of Per Unit & Supply of Bendeka Solution (US$), July’2023
Figure 5-48: US – Unit Cost & Cost of 1 & 6 Cycles of Bendeka Treatment for CLL US$), July’2023
Figure 5-49: US – Unit Cost & Cost of 1 & 6 Cycles of Bendeka Treatment for CLL US$), July’2023
Figure 5-50: US – Ryanodex Orphan Drug Designation & Approval Years
Figure 5-51: US – Monthly Cost of Treatment with Fyarro Injection (US$), July’2023
Figure 5-52: US – Firdapse Orphan Drug Designation & Approval Years
Figure 5-53: US – Cost of Per Unit & Supply of 10mg Firdapse Tablet (US$), July’2023
Figure 5-54: US – Braftovi Orphan Drug Designation & Approval Years
Figure 5-55: US – Cost of Per Unit & Supply of 75mg Braftovi Capsule (US$), July’2023
Figure 5-56: US – Monthly Cost of Melanoma Treatment with Braftovi Capsule (US$), July’2023
Figure 5-57: US – Monthly Cost of Colorectal Cancer Treatment with Braftovi Capsule (US$), July’2023
Figure 5-58: US – Cost of Per Unit & Supply of 15mg Mektovi Tablet (US$), July’2023
Figure 5-59: US – Monthly Cost of Melanoma Treatment with Mektovi Tablet (US$), July’2023
Figure 5-60: US – Evrysdi Orphan Drug Designation & Approval Years
Figure 5-61: US – Cost of Per Unit & Supply of 0.75mg/mL Evrysdi Solution (US$), July’2023
Figure 5-62: US – Hetlioz Orphan Drug Designation & Approval Years by Indication
Figure 5-63: US – Cost of Per Unit & Supply of 20mg Hetlioz Capsule (US$), July’2023
Figure 5-64: US – Cost of Per Unit & Supply of 20mg Hetlioz LQ Oral Suspension (US$), July’2023
Figure 5-65: US – Monthly Cost of Melanoma Treatment with Hetlioz Capsule (US$), July’2023
Figure 5-66: Yervoy – First Approval by Indication
Figure 5-67: US – Cost of Per Unit & Supply of Yervoy Solution (US$), July’2023
Figure 5-68: US – Lorbrena Orphan Drug Designation & Approval Years
Figure 5-69: US – Cost of Per Unit & Supply of Lorbrena Tablet (US$), July’2023
Figure 5-70: US – Monthly & Yearly Cost of Treatment with Lorbrena Tablet (US$), July’2023
Figure 5-71: US – Terlivaz Orphan Drug Designation & Approval Years
Figure 5-72: US – Brukinsa Orphan Drug Designation & Approval Years by Indication
Figure 5-73: US – Cost of Per Unit & Supply of Brukinsa Capsule (US$), July’2023
Figure 5-74: US – Monthly & Yearly Cost of Treatment with Brukinsa (US$), July’2023
Figure 5-75: US – Viltepso Orphan Drug Designation & Approval Years
Figure 5-76: US – Monthly & Yearly Cost of Treatment with Viltepso (US$), July’2023
Figure 5-77: US – Eylea Orphan Drug Designation & Approval Years
Figure 5-78: US – Cost of Per Unit & Supply of Eylea Solution (US$), July’2023
Figure 5-79: US – Monthly & Yearly Cost of Treatment with Viltepso (US$), July’2023
Figure 5-80: US – Evkeeza Orphan Drug Designation & Approval Years
Figure 5-81: US – Cost of Per Unit & Supply of Evkeeza Solution (US$), July’2023
Figure 5-82: US – Sogroya Orphan Drug Designation & Approval Years
Figure 5-83: US – Cost of Per Unit & Supply of Sogroya Solution (US$), July’2023
Figure 5-84: US – Skytrofa Orphan Drug Designation & Approval Years
Figure 5-85: US – Cost of Per Unit & Supply of Skytrofa Injection (US$), July’2023
Figure 5-86: US – Cost of Per Unit & Supply of Avastin Solution (US$), July’2023
Figure 5-87: US – Vyvgart Orphan Drug Designation & Approval Years
Figure 5-88: US – Cost of Per Unit & Supply of Vyvgart Solution (US$), July’2023
Figure 5-89: US – Monthly Cost of Treatment with Vyvgart (US$), July’2023
Figure 5-90: US – Tpoxx Orphan Drug Designation & Approval Years
Figure 5-91: US – Koselugo Orphan Drug Designation & Approval Years
Figure 5-92: US – Cost of Per Unit & Supply of 10mg Capsules of Koselugo (US$), July’2023
Figure 5-93: US – Cost of Per Unit & Supply of 25mg Capsules of Koselugo (US$), July’2023
Figure 5-94: US – Monthly Cost of Treatment with Koselugo by BSA (US$), July’2023
Figure 5-95: US – Actemra Orphan Drug Designation & Approval Years
Figure 5-96: US – Cost of Per Unit & Supply of 20 mg/mL Vials of Actemra IV Solution (US$), July’2023
Figure 5-97: US – Cost of Per Unit & Supply of 162 mg/0.9 mL Prefilled Syringe of Actemra Subcutaneous Solution (ACTpen) (US$), July’2023
Figure 5-98: US – Tecentriq Orphan Drug Designation & Approval Years
Figure 5-99: US – Cost of Per Unit & Supply of Tecentriq Intravenous Solution (US$), July’2023
Figure 5-100: US – Qinlock Orphan Drug Designation & Approval Years
Figure 5-101: US – Cost of Per Unit & Supply of Qinlock Tablets (US$), July’2023
Figure 5-102: US – Unit, Monthly & Annual Cost of Treatment with Qinlock (US$), July’2023
Figure 5-103: US – Wakix Orphan Drug Designation & Approval Years
Figure 5-104: US – Cost of Per Unit & Supply of Wakix Tablets (US$), July’2023
Figure 5-105: US – Kimmtrak Orphan Drug Designation & Approval Years
Figure 5-106: US – Cost of Per Unit & Supply of Kimmtrak (US$), July’2023
Figure 5-107: US – Elahere Orphan Drug Designation & Approval Years
Figure 5-108: US – Cost of Per Unit & Supply of 100 mg/20 mL Elahere Solution (US$), July’2023
Figure 5-109: US - Price for Single Unit of Polivy 30 mg & 140 mg Intravenous Powder for Injection (US$), July’2023
Figure 5-110: US – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia with 30 mg Polivy Powder (US$), July’2023
Figure 5-111: US – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia with 140 mg Polivy Powder (US$), May’2023
Figure 5-112: US – Enhertu Orphan Drug Designation & Approval Years
Figure 5-113: Enhertu – Cost of Single Treatment Cycle & Annual Treatment (US$), July’2023
Figure 5-114: US – Jakafi Orphan Drug Designation & Approval Years
Figure 5-115: US – Cost of Per Unit & Supply of Different Jakafi Doses (US$), July’2023
Figure 5-116: Jakafi – Cost of Monthly & Annual Treatment (US$), July’2023
Figure 5-117: US – Kalydeco Orphan Drug Designation & Approval Years
Figure 5-118: US – Cost of Per Unit & Supply of Kalydeco Oral Granule & Tablet (US$), July’2023
Figure 5-119: Kalydeco – Cost of Monthly & Annual Treatment (US$), July’2023
Figure 5-120: US – Cost of Per Unit & Supply of Symdeko Oral Tablet (US$), July’2023
Figure 5-121: US – Trikafta Orphan Drug Designation & Approval Years
Figure 5-122: US – Cost of Per Unit & Supply of Trikafta Oral Granule & Tablet (US$), July’2023
Figure 5-123: US – Orkambi Orphan Drug Designation & Approval Years
Figure 5-124: US – Cost of Per Unit & Supply of Orkambi Oral Granule & Tablet (US$), July’2023
Figure 5-125: US – Hemgenix Orphan Drug Designation & Approval Years
Figure 5-126: US – Voxzogo Orphan Drug Designation & Approval Years
Figure 5-127: US – Cost of Per Unit & Supply of Voxzogo Powder (US$), July’2023
Figure 5-128: US – Actimmune Orphan Drug Designation & Approval Years
Figure 5-129: US – Cost of Per Unit & Supply of Actimmune Solution (US$), July’2023
Figure 5-130: US – Actimmune Orphan Drug Designation & Approval Years
Figure 5-131: US – Cost of per Unit of Reblozyl powder (US$), July’2023
Figure 5-132: US – Monthly & Annual Cost of Treatment with Reblozyl (US$), July’2023
Figure 5-133: US – Repatha Orphan Drug Designation & Approval Years
Figure 5-134: US – Cost of Per Unit & Supply of Repatha (US$), July’2023
Figure 5-135: US – Monthly & Annual Cost of Repatha Treatment in Adults with Established Cardiovascular Disease or Primary Hyperlipidemia (US$), July’2023
Figure 5-136: US – Monthly & Annual Cost of Repatha Treatment for HoFH (US$), July’2023
Figure 5-137: US – Rebyota Orphan Drug Designation & Approval Years
Figure 5-138: US – Cost of Per Unit & Supply of Rebyota (US$), July’2023
Figure 5-139: US – Cayston Orphan Drug Designation & Approval Years
Figure 5-140: US – Cost of Per Unit & Supply of Cayston Powder (US$), July’2023
Figure 5-141: US – Sylvant Orphan Drug Designation & Approval Years
Figure 5-142: US – Cost of Per Unit & Supply of Sylvant Powder (US$), July’2023
Figure 5-143: US – Cost of Monthly & Yearly Treatment with Sylvant US$), July’2023
Figure 5-144: US – Mylotarg Orphan Drug Designation & Approval Years
Figure 5-145: US – Cost of Per Unit & Supply of Mylotarg Powder (US$), July’2023
Figure 5-146: US – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML with Mylotarg (US$), July’2023
Figure 5-147: US – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML with Mylotarg (US$), July’2023
Figure 5-148: US – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML with Mylotarg (US$), July’2023
Figure 5-149: US – Besremi Orphan Drug Designation & Approval Years
Figure 5-150: US – Cost of Single Dose, Monthly & Yearly Treatment with Besremi (US$), July’2023
Figure 5-151: US – Ravicti Orphan Drug Designation & Approval Years
Figure 5-152: US – Cost of Per Unit & Supply of Ravicti (US$), July’2023
Figure 5-153: US – Cost of Per Unit & Supply of Tazverik Tablet (US$), July’2023
Figure 5-154: US – Luxturna Orphan Drug Designation & Approval Years
Figure 5-155: US – Zynteglo Orphan Drug Designation & Approval Years
Figure 5-156: US – Empaveli Orphan Drug Designation & Approval Years
Figure 5-157: US – Cost of Per Unit & Supply of Empaveli Solution (US$), July’2023
Figure 5-158: US – Cost of Single Dose, Monthly & Yearly Treatment with Empaveli (US$), July’2023
Figure 5-159: US – Ninlaro Orphan Drug Designation & Approval Years
Figure 5-160: US – Cost of Per Unit & Supply of Ninlaro Capsule (US$), July’2023
Figure 5-161: US – Cost of Single Dose, Monthly & Yearly Treatment with Empaveli (US$), July’2023
Figure 5-162: US – Otezla Orphan Drug Designation & Approval Years
Figure 5-163: US – Cost of Per Unit & Supply of Otezla tablet (US$), July’2023
Figure 5-164: US – Arzerra Orphan Drug Designation & Approval Years
Figure 5-165: US – Cost of Per Unit & Supply of Arzerra Solution (US$), July’2023
Figure 5-166: US – Macrilen Orphan Drug Designation & Approval Years
Figure 5-167: US – Cost of Per Unit & Supply of Macrilen Granules (US$), July’2023
Figure 5-168: US – Tagrisso Orphan Drug Designation & Approval Years
Figure 5-169: US – Cost of Per Unit & Supply of Tagrisso Tablets (US$), July’2023
Figure 5-170: US – Tagrisso Monthly, Yearly & Full Course Treatment Cost (US$), July’2023
Figure 5-171: US – Gammagard Liquid Orphan Drug Designation & Approval Years
Figure 5-172: US – Cost of Per Unit & Supply of Different Gammagard Liquid Vials (US$), July’2023
Figure 5-173: US – Fintepla Orphan Drug Designation & Approval Years
Figure 5-174: US – Cost of Per Unit & Supply of Fintepla Solution (US$), July’2023
Figure 5-175: US – Daybue Orphan Drug Designation & Approval Years
Figure 5-176: US – Takhzyro Orphan Drug Designation & Approval Years
Figure 5-177: US – Cost of Per Unit & Supply of Takhzyro Solution (US$), July’2023
Figure 5-178: US – Cyramza Orphan Drug Designation & Approval Years
Figure 5-179: US – Cost of Per Unit & Supply of Cyramza Solution (US$), July’2023
Figure 5-180: US – Hyftor Orphan Drug Designation & Approval Years
Figure 5-181: US – Cost of Per Unit & Supply of Hyftor Gel (US$), July’2023
Figure 5-182: US – Prevymis Orphan Drug Designation & Approval Years
Figure 5-183: US – Cost of Per Unit & Supply of Prevymis Solution (US$), July’2023
Figure 5-184: US – Cost of Per Unit & Supply of Prevymis Tablets (US$), July’2023
Figure 5-185: US – Prevymis Orphan Drug Designation & Approval Years
Figure 5-186: US – Cost of Initial, Subsequent & Annual Treatment with Zynlonta (US$), July’2023
Figure 5-187: US – Copiktra Orphan Drug Designation & Approval Years
Figure 5-188: US – Cost of Per Unit & Supply of Copiktra Capsules (US$), July’2023
Figure 5-189: US – Cost of Monthly & Annual Treatment with Copiktra (US$), July’2023
Figure 5-190: US – Tepezza Orphan Drug Designation & Approval Years
Figure 5-191: US – Cost of Single, Initial & Subsequent Doses of Copiktra (US$), July’2023
Figure 5-192: US – Mycapssa Orphan Drug Designation & Approval Years
Figure 5-193: US – Cost of Per Unit & Supply of Mycapssa Capsules (US$), July’2023
Figure 5-194: US – Juxtapid Orphan Drug Designation & Approval Years
Figure 5-195: US – Cost of Per Unit & Supply of Juxtapid Capsules (US$), July’2023
Figure 5-196: US – Myalept Orphan Drug Designation & Approval Years
Figure 5-197: US – Jelmyto Orphan Drug Designation & Approval Years
Figure 5-198: US – Mitosol Orphan Drug Designation & Approval Years
Figure 5-199: US – Cost of Per Unit & Supply of Mitosol Kit (US$), July’2023
Figure 5-200: US – Empliciti Orphan Drug Designation & Approval Years
Figure 5-201: US – Cost of Per Unit & Supply of Empliciti Powders (US$), July’2023
Figure 5-202: Empliciti – Cost of Treatment (US$), July’2023
Figure 5-203: US – Kcentra Orphan Drug Designation & Approval Years
Figure 5-204: US – Kyprolis Orphan Drug Designation & Approval Years by Indications
Figure 5-205: US – Cost Per Supply of 10mg, 30mg & 60mg Kyprolis (US$), July’2023
Figure 5-206: US – Enspryng Orphan Drug Designation & Approval Years by Indications
Figure 5-207: US – Cost of Treatment with Enspryng (US$), July’2023
Figure 5-208: US – Sirturo Orphan Drug Designation & Approval Years by Indications
Figure 5-209: US – Cost of Per Unit & Supply of 20mg & 100mg Sirturo Tablets (US$), July’2023
Figure 5-210: US – Tavalisse Orphan Drug Designation & Approval Years by Indications
Figure 5-211: US – Cost of Per Unit & Supply of Tavalisse Tablets (US$), July’2023
Figure 5-212: US – Gleolan Orphan Drug Designation & Approval Years by Indications
Figure 5-213: US – Keveyis Orphan Drug Designation & Approval Years
Figure 5-214: US – Cost of Per Unit & Supply of Keveyis Tablets (US$), July’2023
Figure 5-215: US – Zolgensma Orphan Drug Designation & Approval Years
Figure 5-216: US – Darzalex Orphan Drug Designation & Approval Years
Figure 5-217: US – Cost of Per Unit & Supply of Darzalex Solution (US$), July’2023
Figure 5-218: US – Darzalex Orphan Drug Designation & Approval Years
Figure 5-219: US – Doptelet Orphan Drug Designation & Approval Years
Figure 5-220: US – Cost of Per Unit & Supply of Doptelet Tablet (US$), July’2023
Figure 5-221: US – Endari Orphan Drug Designation & Approval Years
Figure 5-222: US – Cost of Per Unit & Supply of Endari Powder (US$), July’2023
Figure 5-223: US – NutreStore Orphan Drug Designation & Approval Years
Figure 5-224: US – Cost of Per Unit & Supply of NutreStore (US$), July’2023
Figure 5-225: US – Lymphoseek Orphan Drug Designation & Approval Years
Figure 5-226: US – Krystexxa Orphan Drug Designation & Approval Years
Figure 5-227: US – Cost of Treatment with Krystexxa (US$), July’2023
Figure 5-228: US – Krystexxa Orphan Drug Designation & Approval Years
Figure 5-229: US – Cost of Per Unit & Supply of Korlym (US$), July’2023
Figure 5-230: US – Monthly & Yearly Korlym Treatment Cost (US$), July’2023
Figure 5-231: US – Kalbitor Orphan Drug Designation & Approval Years
Figure 5-232: US – Livtencity Orphan Drug Designation & Approval Years
Figure 5-233: US – Cost of Per Unit & Supply of Livtencity (US$), July’2023
Figure 5-234: US – Monthly & Yearly Korlym Treatment Cost (US$), July’2023
Figure 5-235: US – Enjaymo Orphan Drug Designation & Approval Years
Figure 5-236: US – Cost of Per Unit & Supply of Enjaymo (US$), July’2023
Figure 5-237: US – Rethymic Orphan Drug Designation & Approval Years
Figure 5-238: US – Coartem Orphan Drug Designation & Approval Years
Figure 5-239: US – Cost of Per Unit & Supply of Coartem (US$), July’2023
Figure 5-240: US – Nulibry Orphan Drug Designation & Approval Years
Figure 5-241: US – Inmazeb Orphan Drug Designation & Approval Years
Figure 5-242: US – Valtoco Orphan Drug Designation & Approval Years
Figure 5-243: US – Cost of Per Unit & Supply of Valtoco (US$), July’2023
Figure 5-244: US – Detectnet Orphan Drug Designation & Approval Years
Figure 5-245: US – Folotyn Orphan Drug Designation & Approval Years
Figure 5-246: US – Cost of Per Unit & Supply of Folotyn (US$), July’2023
Figure 5-247: US – Cost of Single Infusion & 6-Cycle Treatment with Folotyn US$), July’2023
Figure 5-248: US – Cystadane Orphan Drug Designation & Approval Years
Figure 5-249: US – Cost of Per Unit & Supply of Cystadane (US$), July’2023
Figure 5-250: US – Cystaran Orphan Drug Designation & Approval Years
Figure 5-251: US – Cost of Per Unit & Supply of Cystaran (US$), July’2023
Figure 5-252: US – Voraxaze Orphan Drug Designation & Approval Years
Figure 5-253: US – Cost of Treatment with Voraxaze (US$), July’2023
Figure 5-254: US – Mepron Orphan Drug Designation & Approval Years
Figure 5-255: US – Cost of Per Unit & Supply of Mepron (US$), July’2023
Figure 5-256: US – Vistogard Orphan Drug Designation & Approval Years
Figure 5-257: US – Cost of Per Unit & Supply of Mepron (US$), July’2023
Figure 5-258: US – Xuriden Orphan Drug Designation & Approval Years
Figure 5-259: US – Cost of Per Unit & Supply of Mepron (US$), July’2023
Figure 5-260: US – Xatmep Orphan Drug Designation & Approval Years
Figure 5-261: US – Cost of Per Unit & Supply of Xatmep (US$), July’2023
Figure 5-262: US – Purixan Orphan Drug Designation & Approval Years
Figure 5-263: US – Cost of Per Unit & Supply of Purixan (US$), July’2023
Figure 5-264: US – Cost of Per Unit & Supply of Erwinaze (US$), July’2023
Figure 5-265: US – Ascor Orphan Drug Designation & Approval Years
Figure 5-266: US – Cost of Per Unit & Supply of Ascor (US$), July’2023
Figure 5-267: US – Tepadina Orphan Drug Designation & Approval Years
Figure 5-268: US – Cost of Per Supply of Tepadina (US$), July’2023
Figure 5-269: US – BAT Orphan Drug Designation & Approval Years
Figure 5-270: US – Busulfex Orphan Drug Designation & Approval Years
Figure 5-271: US – Cost of Per Unit & Supply of Busulfex (US$), July’2023
Figure 5-272: US – Lipiodol Orphan Drug Designation & Approval Years
Figure 5-273: US – Cost of Per Unit & Supply of Lipiodol (US$), July’2023
Figure 5-274: US – Doxil Orphan Drug Designation & Approval Years
Figure 5-275: US – Cost of Per Unit & Supply of Doxil (US$), July’2023
Figure 5-276: US – Nymalize Orphan Drug Designation & Approval Years
Figure 5-277: US – Cost of Per Unit & Supply of 30 mg/5 mL Nymalize (US$), July’2023
Figure 5-278: US – Cost of Per Unit & Supply of 60 mg/10 mL Nymalize (US$), July’2023
Figure 5-279: US – Priftin Orphan Drug Designation & Approval Years
Figure 5-280: US – Cost of Per Unit & Supply of Priftin (US$), July’2023
Figure 5-281: US – Gralise Orphan Drug Designation & Approval Years
Figure 5-282: US – Cost of Per Unit & Supply of Priftin (US$), July’2023
Figure 5-283: US – Gralise Orphan Drug Designation & Approval Years
Figure 5-284: US – Cost of Per Unit & Supply of Galzin (US$), July’2023
Figure 5-285: US – NeoProfen Orphan Drug Designation & Approval Years
Figure 5-286: US – Cost of Per Unit & Supply of NeoProfen (US$), July’2023
Figure 5-287: US – Photofrin Orphan Drug Designation & Approval Years
Figure 5-288: US – Retisert Orphan Drug Designation & Approval Years
Figure 5-289: US – Elmiron Orphan Drug Designation & Approval Years
Figure 5-290: US – Cost of Per Unit & Supply of Elmiron (US$), July’2023
Figure 5-291: US – Cost of Per Unit & Supply of Extraneal (US$), July’2023
Figure 5-292: US – Azedra Orphan Drug Designation & Approval Years
Figure 5-293: US – Elelyso Orphan Drug Designation & Approval Years
Figure 5-294: US - Cost of Treatment with Elelyso (US$), July’2023
Figure 5-295: US – Tecentriq Orphan Drug Designation & Approval Years
Figure 5-296: US – Cost of Per Unit & Supply of Pedmark Intravenous Solution (US$), July’2023
Figure 5-297: US – Palynziq Orphan Drug Designation & Approval Years
Figure 5-298: US – Cost of Per Unit & Supply of 2.5mg & 10mg Palynziq Subcutaneous Solutions (US$), July’2023
Figure 5-299: US – Cost of Per Unit & Supply of 20mg Palynziq Subcutaneous Solution (US$), July’2023
Figure 5-300: US – Spinraza Orphan Drug Designation & Approval Years
Figure 5-301: US – Cost of Per Unit & Supply of Spinraza (US$), July’2023
Figure 5-302: US - Cost of Treatment with Spinraza (US$), July’2023
Figure 5-303: US - Cost of Treatment with Elzonris (US$), July’2023
Figure 5-304: US – Cost of Per Unit & Supply of Rituxan (US$), July’2023
Figure 5-305: US – Rezlidhia Orphan Drug Designation & Approval Years
Figure 5-306: US – Cost of Per Unit & Supply of Rezlidhia (US$), July’2023
Figure 5-307: US - Cost of Treatment with Rezlidhia (US$), July’2023
Figure 5-308: US – Triptodur Orphan Drug Designation & Approval Years
Figure 5-309: US – Tecartus Orphan Drug Designation & Approval Years
Figure 5-310: US – Cresemba Orphan Drug Designation & Approval Years
Figure 5-311: US – Cost of Per Unit & Supply of Cresemba (US$), July’2023
Figure 5-312: US - Cost of Treatment with Cresemba (US$), July’2023
Figure 5-313: US – Cost of Per Unit & Supply of Opsumit (US$), July’2023
Figure 5-314: US - Cost of Treatment with Opsumit (US$), July’2023
Figure 5-315: US – Exservan Orphan Drug Designation & Approval Years
Figure 5-316: US - Cost of Treatment with Exservan (US$), July’2023
Figure 5-317: US – Uplizna Orphan Drug Designation & Approval Years
Figure 5-318: US – Cost of Per Unit & Supply of Uplizna (US$), July’2023
Figure 5-319: US – Givlaari Orphan Drug Designation & Approval Years
Figure 5-320: US - Cost of Treatment with Givlaari (US$), July’2023
Figure 5-321: US – Oxlumo Orphan Drug Designation & Approval Years
Figure 5-322: US – Cost of Per Unit & Supply of Oxlumo (US$), July’2023
Figure 5-323: US - Cost of Treatment with Oxlumo (US$), July’2023
Figure 5-324: US – Velcade Orphan Drug Designation & Approval Years
Figure 5-325: US – Exondys 51 Orphan Drug Designation & Approval Years
Figure 5-326: US – Cost of Per Unit & Supply of Exondys 51 (US$), July’2023
Figure 5-327: US - Cost of Treatment with Exondys 51 (US$), July’2023
Figure 5-328: US – Vyondys 53 Orphan Drug Designation & Approval Years
Figure 5-329: US – Cost of Per Unit & Supply of Vyondys 53 (US$), July’2023
Figure 5-330: US - Cost of Treatment with Vyondys 53 (US$), July’2023
Figure 5-331: US – Amondys 45 Orphan Drug Designation & Approval Years
Figure 5-332: US – Cost of Per Unit & Supply of Amondys 45 (US$), July’2023
Figure 5-333: US - Cost of Treatment with Amondys 45 (US$), July’2023
Figure 5-334: US – Besponsa Orphan Drug Designation & Approval Years
Figure 5-335: US – Cost of Treatment with Besponsa (US$), July’2023
Figure 5-336: US – Epidiolex Orphan Drug Designation & Approval Years
Figure 5-337: US – Cost of Per Unit & Supply of Epidiolex (US$), July’2023
Figure 5-338: US – Xyrem Orphan Drug Designation & Approval Years
Figure 5-339: US – Cost of Per Unit & Supply of Xyrem (US$), July’2023
Figure 5-340: US – Xywav Orphan Drug Designation & Approval Years
Figure 5-341: US – Cost of Per Unit & Supply of Xywav (US$), July’2023
Figure 5-342: US – Vyxeos Orphan Drug Designation & Approval Years
Figure 5-343: US – Cost of Per Unit & Supply of Vyxeos (US$), July’2023
Figure 5-344: US – Unituxin Orphan Drug Designation & Approval Years
Figure 5-345: US – Cost of Per Unit & Supply of Unituxin (US$), July’2023
Figure 5-346: US – Cost of Treatment with Unituxin (US$), July’2023
Figure 5-347: US – Alimta Orphan Drug Designation & Approval Years
Figure 5-348: US – Cost of Supply of Alimta (US$), July’2023
Figure 5-349: US – Aliqopa Orphan Drug Designation & Approval Years
Figure 5-350: US – Cost of Treatment with Aliqopa (US$), July’2023
Figure 5-351: US – Aliqopa Orphan Drug Designation & Approval Years
Figure 5-352: US – Cost of Per Unit & Supply of Oncaspar (US$), July’2023
Figure 5-353: US – Rylaze Orphan Drug Designation & Approval Years
Figure 5-354: US – Cost of Supply of Rylaze (US$), July’2023
Figure 5-355: US – Rylaze Orphan Drug Designation & Approval Years
Figure 5-356: US – Cost of Treatment with Vonjo (US$), July’2023
Figure 5-357: US – Pyrukynd Orphan Drug Designation & Approval Years
Figure 5-358: US – Cost of Per Unit & Supply of Pyrukynd (US$), July’2023
Figure 5-359: US – Uptravi Orphan Drug Designation & Approval Years
Figure 5-360: US – Cost of Supply of Uptravi IV (US$), July’2023
Figure 5-361: US – Cost of Per Unit & Supply of 200mcg Uptravi Oral Tablets (US$), July’2023
Figure 5-362: US – Cost of Per Unit & Supply of 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg & 1600mcg Uptravi Oral Tablets (US$), July’2023
Figure 5-363: US – Xermelo Orphan Drug Designation & Approval Years
Figure 5-364: US – Cost of Treatment with Xermelo (US$), July’2023
Figure 5-365: US – Gilotrif Orphan Drug Designation & Approval Years
Figure 5-366: US – Cost of Per Unit & Supply of Gilotrif Oral Tablets (US$), July’2023
Figure 5-367: US – Cost of Per Unit & Supply of Oxbryta Oral Tablets (US$), July’2023
Figure 5-368: US – Wilate Orphan Drug Designation & Approval Years
Figure 5-369: US – Stivarga Orphan Drug Designation & Approval Years
Figure 5-370: US – Cost of Per Unit & Supply of Oxbryta Oral Tablets (US$), July’2023
Figure 5-371: US – Alkindi Sprinkle Orphan Drug Designation & Approval Years
Figure 5-372: US – Cost of Per Unit & Supply of Alkindi Sprinkle (US$), July’2023
Figure 5-373: US – Gamifant Orphan Drug Designation & Approval Years
Figure 5-374: US – Cost of Per Unit & Supply of Gamifant (US$), July’2023
Figure 5-375: US – Monthly & Yearly Cost of Treatment with Gamifant (US$), July’2023
Figure 5-376: US – Turalio Orphan Drug Designation & Approval Years
Figure 5-377: US – Cost of Per Unit & Supply of Turalio (US$), July’2023
Figure 5-378: US – Yondelis Orphan Drug Designation & Approval Years
Figure 5-379: US – Cost per Yondelis Injection (US$), July’2023
Figure 5-380: US – Yondelis Orphan Drug Designation & Approval Years
Figure 5-381: US – Cost of Per Unit & Supply of NovoSeven RT (US$), July’2023
Figure 5-382: US – Yondelis Orphan Drug Designation & Approval Years
Figure 5-383: US – Cost of Per Unit & Supply of Tabrecta (US$), July’2023
Figure 5-384: US – Rebinyn Orphan Drug Designation & Approval Years
Figure 5-385: US – Onureg Orphan Drug Designation & Approval Years
Figure 5-386: US – Cost of Per Unit & Supply of Onureg (US$), July’2023
Figure 5-387: US – Cost per Onureg Cycle (US$), July’2023
Figure 5-388: US – Cabometyx Orphan Drug Designation & Approval Years
Figure 5-389: US – Cost of Per Unit & Supply of Cabometyx (US$), July’2023
Figure 5-390: US – Cabometyx Orphan Drug Designation & Approval Years
Figure 5-391: US – Cost of Per Unit & Supply of Cometriq (US$), July’2023
Figure 5-392: US – Orenitram Orphan Drug Designation & Approval Years
Figure 5-393: US – Cost of Per Unit & Supply of 0.125mg Orenitram Tablets (US$), July’2023
Figure 5-394: US – Cost of Per Unit & Supply of 0.25mg Orenitram Tablets (US$), July’2023
Figure 5-395: US – Cost of Per Unit & Supply of 1mg Orenitram Tablets (US$), July’2023
Figure 5-396: US – Cost of Per Unit & Supply of 2.5mg Orenitram Tablets (US$), July’2023
Figure 5-397: US – Cost of Per Unit & Supply of 5mg Orenitram Tablets (US$), July’2023
Figure 5-398: US – Remodulin Orphan Drug Designation & Approval Years
Figure 5-399: US – Cost of Per Unit & Supply of Remodulin Injection (US$), July’2023
Figure 5-400: US – Tavneos Orphan Drug Designation & Approval Years
Figure 5-401: US – Cost of Per Unit & Supply of Tavneos (US$), July’2023
Figure 5-402: US – Impavido Orphan Drug Designation & Approval Years
Figure 5-403: US – Cost of Per Unit & Supply of Impavido (US$), July’2023
Figure 5-404: US – Carvykti Orphan Drug Designation & Approval Years
Figure 5-405: US – Xiaflex Orphan Drug Designation & Approval Years
Figure 5-406: US – Hemlibra Orphan Drug Designation & Approval Years
Figure 5-407: US – Cost of Supply of Hemlibra (US$), July’2023
Figure 5-408: US – Cost of Loading & Maintenance Dose of Hemlibra (US$), July’2023
Figure 5-409: US – Recorlev Orphan Drug Designation & Approval Years
Figure 5-410: US – Cost per Unit & Supply of Recorlev (US$), July’2023
Figure 5-411: US – Exkivity Orphan Drug Designation & Approval Years
Figure 5-412: US – Cost per Unit & Supply of Exkivity (US$), July’2023
Figure 5-413: US – Kymriah Orphan Drug Designation & Approval Years
Figure 5-414: US – Brineura Orphan Drug Designation & Approval Years
Figure 5-415: US – Monthly & Yearly Cost of Treatment with Brineura (US$), July’2023
Figure 5-416: US – Istodax Orphan Drug Designation & Approval Years
Figure 5-417: US – Monthly Cost of Treatment with Istodax (US$), July’2023
Figure 5-418: US – Bosulif Orphan Drug Designation & Approval Years
Figure 5-419: US – Cost per Unit & Supply of Bosulif (US$), July’2023
Figure 5-420: US – Idhifa Orphan Drug Designation & Approval Years
Figure 5-421: US – Monthly & Yearly Cost of Treatment with Idhifa (US$), July’2023
Figure 5-422: US – Arcalyst Orphan Drug Designation & Approval Years
Figure 5-423: US – Cost per Unit & Supply of Arcalyst (US$), July’2023
Figure 5-424: US – Xgeva Orphan Drug Designation & Approval Years
Figure 5-425: US – Cost per Unit & Supply of Xgeva (US$), July’2023
Figure 5-426: US – Dojolvi Orphan Drug Designation & Approval Years
Figure 5-427: US – Cost per Unit & Supply of Dojolvi (US$), July’2023
Figure 5-428: US – Dojolvi Orphan Drug Designation & Approval Years
Figure 5-429: US – Cost per Unit & Supply of Pomalyst (US$), July’2023
Figure 5-430: US – Monthly Cost of Treatment of Multiple Myeloma & Kaposi Sarcoma with Pomalyst (US$), July’2023
Figure 5-431: US – Cost per Unit & Supply of Gleevec (US$), July’2023
Figure 5-432: US – Nexavar Orphan Drug Designation & Approval Years
Figure 5-433: US – Cost per Unit & Supply of Nexavar (US$), July’2023
Figure 5-434: US – Nexavar Orphan Drug Designation & Approval Years
Figure 5-435: US – Cost per Unit & Supply of Treanda (US$), July’2023
Figure 5-436: US – Cost of Monthly & Full Treatment Course with Treanda (US$), July’2023
Figure 5-437: US – Nexavar Orphan Drug Designation & Approval Years
Figure 5-438: US – Cost per Unit & Supply of Treanda (US$), July’2023
Figure 5-439: US – Botox Orphan Drug Designation & Approval Years
Figure 5-440: US – Cost of Supply of Botox (US$), July’2023
Figure 5-441: US – Orfadin Orphan Drug Designation & Approval Years
Figure 5-442: US – Cost per Unit & Supply of Orfadin Capsules (US$), July’2023
Figure 5-443: US – Cost per Unit & Supply of Orfadin Suspension (US$), July’2023
Figure 5-444: US – Promacta Orphan Drug Designation & Approval Years
Figure 5-445: US – Cost per Unit & Supply of 12.5mg & 25mg Promacta Tablets (US$), July’2023
Figure 5-446: US – Cost per Unit & Supply of 50mg Promacta Tablet (US$), July’2023
Figure 5-447: US – Cost per Unit & Supply of 75mg Promacta Tablet (US$), July’2023
Figure 5-448: US – Cost per Unit & Supply of Promacta Powder (US$), July’2023
Figure 5-449: US – Eloctate Orphan Drug Designation & Approval Years
Figure 5-450: US – Carbaglu Orphan Drug Designation & Approval Years
Figure 5-451: US – Cost per Unit & Supply of Carbaglu (US$), July’2023
Figure 5-452: US – Xospata Orphan Drug Designation & Approval Years
Figure 5-453: US – Cost per Unit & Supply of Xospata (US$), July’2023
Figure 5-454: US – Monthly & Full Course Treatment Cost with Xospata (US$), July’2023
Figure 5-455: US – Defitelio Orphan Drug Designation & Approval Years
Figure 5-456: US – Cost per Unit & Supply of Defitelio (US$), July’2023
Figure 5-457: US – Thalomid Orphan Drug Designation & Approval Years
Figure 5-458: US – Cost per Unit & Supply of 50mg Thalomid Capsule (US$), July’2023
Figure 5-459: US – Cost per Unit & Supply of 100mg & 150mg Thalomid Capsule (US$), July’2023
Figure 5-460: US – Agrylin Orphan Drug Designation & Approval Years
Figure 5-461: US – Cost per Unit & Supply of Agrylin (US$), July’2023
Figure 5-462: US – Monthly Treatment Cost with Agrylin (US$), July’2023
Figure 5-463: US – ReFacto Orphan Drug Designation & Approval Years
Figure 5-464: US – Xyntha Orphan Drug Designation & Approval Years
Figure 5-465: US – Valchlor Orphan Drug Designation & Approval Years
Figure 5-466: US – Cost per Unit & Supply of Valchlor (US$), July’2023
Figure 5-467: US – Antizol Orphan Drug Designation & Approval Years
Figure 5-468: US – Rozlytrek Orphan Drug Designation & Approval Years
Figure 5-469: US – Cost per Unit & Supply of Rozlytrek (US$), July’2023
Figure 5-470: US – Poteligeo Orphan Drug Designation & Approval Years
Figure 5-471: US – Cost per Unit & Supply of Poteligeo (US$), July’2023
Figure 5-472: US – Treatment Costs Associated with Poteligeo (US$), July’2023
Figure 5-473: US – Cost per Unit & Supply of Humira (US$), July’2023
Figure 5-474: US – Kanuma Orphan Drug Designation & Approval Years
Figure 5-475: US – Cost per Unit & Supply of Kanuma (US$), July’2023
Figure 5-476: US – Cost per Unit & Supply of Kanuma (US$), July’2023
Figure 5-477: US – Sensipar Orphan Drug Designation & Approval Years
Figure 5-478: US – Cost per Unit & Supply of Sensipar (US$), July’2023
Figure 5-479: US – Farydak Orphan Drug Designation & Approval Years
Figure 5-480: US – Cost per Unit & Supply of Farydak (US$), July’2023
Figure 5-481: US – Gattex Orphan Drug Designation & Approval Years
Figure 5-482: US – Cost of Supply of Gattex (US$), July’2023
Figure 5-483: US – Crysvita Orphan Drug Designation & Approval Years
Figure 5-484: US – Cost per Unit & Supply of Crysvita (US$), July’2023
Figure 5-485: US – Serostim Orphan Drug Designation & Approval Years
Figure 5-486: US – Cost per Unit & Supply of Serostim (US$), July’2023
Figure 5-487: US – Zorbtive Orphan Drug Designation & Approval Years
Figure 5-488: US – Cost per Unit & Supply of Zorbtive (US$), July’2023
Figure 5-489: US – Caprelsa Orphan Drug Designation & Approval Years
Figure 5-490: US – Cost per Unit & Supply of Caprelsa (US$), July’2023
Figure 5-491: US – Zolinza Orphan Drug Designation & Approval Years
Figure 5-492: US – Cost per Unit & Supply of Zolinza (US$), July’2023
Figure 5-493: US – Vitrakvi Orphan Drug Designation & Approval Years
Figure 5-494: US – Cost per Unit & Supply of Vitrakvi Capsule (US$), July’2023
Figure 5-495: US – Cost per Unit & Supply of Vitrakvi Solution (US$), July’2023
Figure 5-496: US – Obizur Orphan Drug Designation & Approval Years
Figure 5-497: US – Obizur Orphan Drug Designation & Approval Years
Figure 5-498: US – Cost per Unit & Supply of 100mg Vitrakvi Capsule (US$), July’2023
Figure 5-499: US – Cost per Unit & Supply of 140mg, 140mg & 250mg Vitrakvi Capsule (US$), July’2023
Figure 5-500: US – Ventavis Orphan Drug Designation & Approval Years
Figure 5-501: US – Cost per Unit & Supply of Ventavis (US$), July’2023
Figure 5-502: US – Torisel Orphan Drug Designation & Approval Years
Figure 5-503: US – Unit & Monthly Cost of Treatment with Torisel
Figure 5-504: US – Nayzilam Orphan Drug Designation & Approval Years
Figure 5-505: US – Cost per Unit & Supply of Nayzilam (US$), July’2023
Figure 5-506: US – Zokinvy Price per Unit for Oral Capsules of 50mg & 75mg (US$), July’2023
Figure 5-507: Zokinvy - Recommended Dosage, Administration & Treatment Cost per Month (30 Days) for 115 mg/m2 Body Surface Area (US$), July’2023
Figure 5-508: US – Ayvakit Approval History
Figure 5-509: US – Ayvakit Price per Unit for Oral Tablets of 100mg, 200mg & 300mg (US$), July’2023
Figure 5-510: US – Mekinist Orphan Designations
Figure 5-511: US – Mekinist Price per Unit for 30 Oral Tablets of 0.5mg & 2mg (US$), July’2023
Figure 5-512: US – Yescarta Cost per Treatment Regimen (US$), July’2023
Figure 5-513: US – Xifaxan Orphan Drug Designation History
Figure 5-514: US – Xifaxan Price per Unit for 30 Oral Tablets of 200mg (US$), July’2023
Figure 5-515: US – Xifaxan Price per Unit for 60 Oral Tablets of 550mg (US$), July’2023
Figure 5-516: US – Lunsumio Price per Unit for 1 mg/mL of Intravenous Solution (US$), July’2023
Figure 5-517: US - Lunsumio Price per Unit for 30 mg/mL of Intravenous Solution (US$), July’2023
Figure 5-518: Lunsumio – Cost of Treatment for 1 Cycle (21 Days) (US$), July’2023
Figure 5-519: Lunsumio – Cost of Treatment for 8 Cycles (US$), July’2023
Figure 5-520: Bylvay – US Orphan Drug Designation History
Figure 5-521: US – Bylvay Price per Unit for 30 Oral Capsules of 400mcg & 1200mcg (US$), July’2023
Figure 5-522: US – Bylvay Price per Unit for 30 Oral Pellet of 200mcg & 600mcg (US$), July’2023
Figure 5-523: US – Tarpeyo Price per Unit for 120 Oral Capsules of 4mg (US$), July’2023
Figure 5-524: Tarpeyo – Cost of Treatment for 9 Months (US$), July’2023
Figure 5-525: US – Ultomiris Price per Unit for 100mg/mL Intravenous Solution (US$), July’2023
Figure 5-526: US – Cuvrior Price per Unit for 72 Oral Tablets of 300mg (US$), July’2023
Figure 5-527: Bavencio – US Orphan Drug Designation History
Figure 5-528: US – Bavencio Price per Unit for 20mg/mL Intravenous Solution (US$), July’2023
Figure 5-529: Pemazyre – US Orphan Drug Designation History
Figure 5-530: US – Pemazyre Price per Unit for 14 Oral Tablets of 4.5mg, 9mg & 13.5mg (US$), July’2023
Figure 5-531: US – Relyvrio Price per Unit for 7 & 56 Powder for Reconstitution (US$), July’2023
Figure 5-532: US – Inqovi Price per Unit for 5 Oral Tablets of 100mg-35mg (US$), July’2023
Figure 5-533: Inqovi – Cost of Treatment for 4 Cycles (US$), July’2023
Figure 5-534: US – HepaGam B Price per Unit for 1mL & 5mL Injectable Solution (US$), July’2023
Figure 5-535: US – VariZIG Price per Unit for 125 IU (/1.2mL) Intramuscular Solution (US$), July’2023
Figure 5-536: Camzyos – Price per Unit for 30 Oral capsules of 2.5mg, 5mg, 10mg & 15mg (US$), July’2023
Figure 5-537: Camzyos – Recommended Dosage for Initiation Phase, July’2023
Figure 5-538: Camzyos – Recommended Dose for Maintenance Phase, July’2023
Figure 5-539: US – CytoGam Price per Unit for 50mg/mL Intravenous Solution (US$), July’2023
Figure 5-540: Letairis – US Orphan Drug Designation History
Figure 5-541: US – Letairis Price per Unit for 10 & 30 Oral Tablets of 5mg (US$), July’2023
Figure 5-542: US – Letairis Price per Unit for 10 & 30 Oral Tablets of 10mg (US$), July’2023
Figure 5-543: Letairis – Cost of Initial Dose (5mg) & Maximum Dose (10mg) per Month (30 Days) (US$), July’2023
Figure 5-544: US – Mozobil Price per Unit of 20mg/mL Subcutaneous Solution for 1.2mL (US$), July’2023
Figure 5-545: US – Tegsedi Price per Unit of 284mg/1.5mL Subcutaneous Solution for 6mL (US$), July’2023
Figure 5-546: Tegsedi – Treatment Cost per Week & Month (US$), July’2023
Figure 5-547: US – Xenazine Price per Unit for 112 Oral Tablets of 12.5mg & 25mg (US$), July’2023
Figure 5-548: Xenazine – Cost for Recommended Dose of Upto 50mg per Day (US$), July’2023
Figure 5-549: Xenazine – Cost for Recommended Maximum Daily Dose & Single Dose for Extensive & Intermediate CYP2D6 Metabolizers (US$), July’2023
Figure 5-550: Xenazine – Cost for Recommended Daily Dose & Single Dose for Poor CYP2D6 Metabolizers (US$), July’2023
Figure 5-551: US – Increlex Price per Unit for 40mL of 10mg/mL Subcutaneous Solution (US$), July’2023
Figure 5-552: Ethyol – US Orphan Drug Designation History
Figure 5-553: US – Ethyol Price per Unit for 3 Intravenous Powder for Injection of 500mg (US$), July’2023
Figure 5-554: US – Astagraf XL Price per Unit for 30 Oral Capsules of 0.5mg,1mg & 5mg (US$), July’2023
Figure 5-555: US – Prograf Price per Unit for 10mL of 5mg/mL Intravenous Solution (US$), July’2023
Figure 5-556: US – Prograf Price per Unit for 100 Oral Capsules of 0.5mg, 1mg & 5mg (US$), July’2023
Figure 5-557: US – Prograf Price per Unit for 50 Oral Granule for Reconstitution of 0.2mg & 1mg (US$), July’2023
Figure 5-558: US – Ztalmy Price per Unit for 50mg/mL Oral Suspension of 110mL & 550mL (US$), July’2023
Figure 5-559: US – Keytruda Price per Unit for 25mg/mL Intravenous Solution of 4mL & 8mL (US$), July’2023
Figure 5-560: Venclexta – US Orphan Drug Designation History
Figure 5-561: US – Venclexta Price per Unit for 42 Oral Kits of 10mg, 50mg & 100mg (US$), July’2023
Figure 5-562: US – Venclexta Price per Unit for 10mg Oral Tablets (US$), July’2023
Figure 5-563: US – Venclexta Price per Unit for 50mg Oral Tablets (US$), July’2023
Figure 5-564: US – Venclexta Price per Unit for 100mg Oral Tablets (US$), July’2023
Figure 5-565: US – Beleodaq Price per Unit for 1 Powder Injection of 500mg (US$), July’2023
Figure 5-566: Beleodaq – Cost per Dose & Cycle (US$), July’2023
Figure 5-567: US – Radicava Price per Unit for 30mg/100mL Intravenous Solution (US$), July’2023
Figure 5-568: US – Radicava ORS Price per Unit for 105mg/5mL Oral Suspension (US$), July’2023
Figure 5-569: Radicava – Cost per Initial & Subsequent Cycle (US$), July’2023
Figure 5-570: Radicava ORS – Cost per Initial & Subsequent Cycle (US$), July’2023
Figure 5-571: US – Jaypirca Price per Unit for 30 Oral Tablets of 50mg (US$), July’2023
Figure 5-572: US – Jaypirca Price per Unit for 60 Oral Tablets of 100mg (US$), July’2023
Figure 5-573: Jaypirca – Cost per Dose Difference in 50mg & 100mg Oral Tablets (US$), July’2023
Figure 5-574: US – Filspari Price per Unit for 200mg & 400mg of 30 Oral Tablets (US$), July’2023
Figure 5-575: Filspari - Cost of Treatment (US$), July’2023
Figure 5-576: Tibsovo – US Orphan Drug Designation History
Figure 5-577: US – Tibsovo Price per Unit of 250mg for 60 Oral Tablets (US$), July’2023
Figure 5-578: Tibsovo – Cost of Treatment for 1 Month & 6 Months (US$), July’2023
Figure 5-579: US – Joenja Price per Unit of 70mg for 60 Oral Tablets (US$), July’2023
Figure 5-580: US – Abecma Price per Unit for 1 Intravenous Suspension (US$), July’2023
Figure 5-581: US – Spevigo Price per Unit for 15mL of 450mg/7.5mL Intravenous Solution (US$), July’2023
Figure 5-582: US – Apokyn Price per Unit for 10mg/mL Subcutaneous Solution (US$), July’2023
Figure 5-583: US – Prolastin-C Price per Unit of 1 Intravenous Powder for Injection (US$), July’2023
Figure 5-584: US – Prolastin-C Price per Unit for 1 Intravenous Solution (US$), July’2023
Figure 5-585: US – Northera Price per Unit for 90 Oral Capsules of 100mg, 200mg & 300mg (US$), July’2023
Figure 5-586: US – Qutenza Price per Unit for 1 8% Topical Kit (US$), July’2023
Figure 5-587: US – Infasurf Price per Unit for 35.7mg/mL Intratracheal Solution (US$), July’2023
Figure 5-588: Fusilev – US Orphan Drug Designation History
Figure 5-589: US – Fusilev Price per Unit for 1 Powder Injection of 50mg (US$), July’2023
Figure 5-590: US – Corlanor Price per Unit for 140mL Oral liquid (US$), July’2023
Figure 5-591: US – Corlanor Price per Unit for 60 Oral Tablets of 5mg & 7.5mg (US$), July’2023
Figure 5-592: US – Abraxane Price per Unit for 1 Powder Injection of 100mg (US$), July’2023
Figure 5-593: Abraxane – Cost per Dose & Cycle (US$), July’2023
Figure 5-594: US – Esbriet Price per Unit for 270 Oral Capsules of 267mg (US$), July’2023
Figure 5-595: US – Esbriet Price per Unit for 270 Oral Tablets of 267mg (US$), July’2023
Figure 5-596: US – Esbriet Price per Unit for 90 Oral Tablets of 801mg (US$), July’2023
Figure 5-597: US – Idelvion Price per Unit for 1 Intravenous Kit (US$), July’2023
Figure 5-598: US – TOBI Price per Unit for 280mL (56 x 5mL) Inhalation Solution (US$), July’2023
Figure 5-599: US – Mepsevii Price per Unit for 5mL Intravenous solution (US$), July’2023
Figure 5-600: US – Revatio Price per Unit for 12.5mL Intravenous Solution of 10mg (US$), July’2023
Figure 5-601: US – Revatio Price per Unit for 112mL Oral Powder for Reconstitution of 10mg (US$), July’2023
Figure 5-602: US – Revatio Price per Unit for 90 Oral Tablets of 20mg (US$), July’2023
Figure 5-603: US – Isturisa Price per Unit for 1mg Oral Tablets (US$), July’2023
Figure 5-604: US – Isturisa Price per Unit for 5mg Oral Tablets (US$), July’2023
Figure 5-605: US – Isturisa Price per Unit for 10mg Oral Tablets (US$), July’2023
Figure 5-606: US – Cablivi Price per Unit for 1 Injectable Kit (US$), July’2023
Figure 5-607: US – Cystagon Price per Unit for 500 Oral Capsules of 50mg & 150mg (US$), July’2023
Figure 5-608: US – Tretten Price per Unit for 1 Intravenous Powder for Injection (US$), July’2023
Figure 5-609: US – Lumizyme Price per Unit or 1 Intravenous Powder Injection of 50mg (US$), July’2023
Figure 5-610: US – Myozyme Price per Unit for 1 Intravenous Powder Injection of 50mg (US$), July’2023
Figure 5-611: Lumizyme & Myozyme – Cost of Treatment per Dose (US$), July’2023
Figure 5-612: US – Vimizim Price per Unit for 5mL Intravenous Solution of 1mg/mL (US$), July’2023
Figure 5-613: Vimizim – Recommended Cost of Treatment per Dose (US$), July’2023
Figure 5-614: US – Sabril Price per Unit for 50 Oral Powder for Reconstitution of 500mg (US$), July’2023
Figure 5-615: US – Sabril Price per Unit for 100 Oral Tablets of 500mg (US$), July’2023
Figure 5-616: US – Vonvendi Price per Unit for 1 Intravenous Powder for Injection (US$), July’2023
Figure 5-617: US – Natpara Price per Unit for 2 Subcutaneous Powder Injection of 25mcg/dose (US$), July’2023
Figure 5-618: US – Natpara Price per Unit for 2 Subcutaneous Powder Injection of 50mcg/dose (US$), July’2023
Figure 5-619: US – Natpara Price per Unit for 2 Subcutaneous Powder Injection of 75mcg/dose (US$), July’2023
Figure 5-620: US – Natpara Price per Unit for 2 Subcutaneous Powder Injection of 100mcg/dose (US$), July’2023
Figure 5-621: US – Verkazia Price per Unit for 120 Ophthalmic Emulsion of 0.1% (US$), July’2023
Figure 5-622: US – Thyrogen Price per Unit for 2 Intramuscular Powder Injection of 0.9mg (US$), July’2023
Figure 5-623: Thyrogen – Cost per Recommended Dose (US$), July’2023
Figure 5-624: US – Arranon Price per Unit for 50mL Intravenous solution of 5mg/mL (US$), July’2023
Figure 5-625: US – Ixiaro Price per Unit for 0.5mL Intramuscular Suspension (US$), July’2023
Figure 5-626: US – Cinryze Price per Unit for 1 Intravenous powder Injection of 500IU (US$), July’2023
Figure 5-627: Cinryze – Cost per Recommended Dose (US$), July’2023
Figure 5-628: US – Norditropin FlexPro Price per Unit for 1.5mL Subcutaneous Solution of 5mg, 10mg & 15mg (US$), July’2023
Figure 5-629: US – Norditropin FlexPro Price per Unit for 3mL Subcutaneous Solution of 30mg (US$), July’2023
Figure 5-630: US – Dysport Price per Unit for 1 Injectable Powder Injection of 500 Units (US$), July’2023
Figure 5-631: US – Dysport Price per Unit for 1 Intramuscular Powder Injection of 300 Units (US$), July’2023
Figure 5-632: US – Xenpozyme Price per Unit for 1 Intravenous Powder Injection of 20mg (US$), July’2023
Figure 5-633: Xenpozyme – Cost per Recommended Starting Dose & Eighth Dose in Adult Patient (US$), July’2023
Figure 5-634: Xenpozyme – Cost per Recommended Starting Dose & Ninth Dose in Pediatric Patient (US$), July’2023
Figure 5-635: US – Banzel Price per Unit for 460mL Oral Suspension of 40mg/mL (US$), July’2023
Figure 5-636: US – Banzel Price per Unit for 120 Oral Tablets of 200mg & 400mg (US$), July’2023
Figure 5-637: US – Aldurazyme Price per Unit for 5mL Intravenous Solution of 2.9mg (US$), July’2023
Figure 5-638: Aldurazyme – Cost per Recommended Dose (US$), July’2023
Figure 5-639: US – Targretin Price per Dose for 100 Oral Capsules of 75mg (US$), July’2023
Figure 5-640: US – Lumoxiti Price per Unit for 1 Intravenous Powder Injection of 1mg (US$), July’2023
Figure 5-641: Lumoxiti – Cost of Treatment for 1 Cycle & 6 Cycles (US$), July’2023
Figure 5-642: US – Dificid Price per Unit for 136mL Oral granule for Reconstitution of 40mg/mL (US$), July’2023
Figure 5-643: US – Dificid Price per Unit for 20 Oral Tablets of 200mg (US$), July’2023
Figure 5-644: US – Onfi Price per Unit for 120mL Oral Suspension of 2.5mg/mL (US$), July’2023
Figure 5-645: US – Onfi Price per Unit for 100 Oral Tablets of 100mg & 200mg (US$), July’2023
Figure 5-646: US – Evista Price per Unit for 30 Oral Tablets of 60mg (US$), July’2023
Figure 5-647: US – Elitek Price per Unit for 3 Powder Injection of 1.5mg (US$), July’2023
Figure 5-648: US – Elitek Price per Unit for 1 Powder Injection of 7.5mg (US$), July’2023
Figure 5-649: Elitek – Cost of Recommended Dose (US$), July’2023
Figure 5-650: US – Gamunex-C Price per Unit for 10% Injectable Solution of 10mL, 25mL & 50mL(US$), July’2023
Figure 5-651: US – Gamunex-C Price per Unit for 10% Injectable Solution of 100mL, 200mL & 40mL (US$), July’2023
Figure 5-652: US – Alunbrig Price per Unit for 30 Oral Tablets of 90mg-180mg (15 Each) (US$), July’2023
Figure 5-653: US – Alunbrig Price per Unit for 30 Oral Tablets of 30mg & 180mg (US$), July’2023
Figure 5-654: US – Alunbrig Price per Unit for 7 & 30 Oral Tablets of 90mg (US$), July’2023
Figure 5-655: Alunbrig – Cost of Recommended Dose for 7 Days & Subsequent Doses, July’2023
Figure 5-656: US - Noxafil Price per Unit for 16.7mL Intravenous Solution of 18mg/mL (US$), July’2023
Figure 5-657: US – Noxafil Price per Unit for 60 Oral Delayed Release Tablets of 100mg (US$), July’2023
Figure 5-658: US – Noxafil Price per Unit for 8 Oral Delayed Release Powder for Reconstitution of 300mg (US$), July’2023
Figure 5-659: US – Noxafil Price per Unit for 105mL Oral Suspension of 40mg/mL (US$), July’2023
Figure 5-660: US - Vizimpro Price per Unit for 30 Oral tablets of 15mg, 30mg & 45mg (US$), July’2023
Figure 5-661: US – Envarsus XR Price per Unit for 30 & 100 Extended Release Oral Tablets of 0.75mg (US$), July’2023
Figure 5-662: US – Envarsus XR Price per Unit for 30 & 100 Extended Release Oral Tablets of 1mg (US$), July’2023
Figure 5-663: US – Envarsus XR Price per Unit for 30 & 100 Extended Release Oral Tablets of 4mg (US$), July’2023
Figure 5-664: US – Azedra Price per Unit for 1 Intravenous Solution (US$), July’2023
Figure 5-665: US – Albenza Price per Unit for 2 Oral Tablets (US$), July’2023
Figure 5-666: US – Netspot Price per Unit for 1 Intravenous Powder Injection (US$), July’2023
Figure 5-667: US – Trisenox Price per Unit for 60mL Intravenous Solution of 2mg/mL (US$), July’2023
Figure 5-668: US – Buphenyl Price per Unit for 266g Oral Powder for Reconstitution of 0.94g/g (US$), July’2023
Figure 5-669: US – Buphenyl Price per Unit for 250 Oral Tablets of 500mg (US$), July’2023
Figure 5-670: US – Ammonul Price per Unit for 50mL Intravenous Solution of 10%- 10% (US$), July’2023
Figure 5-671: US – Synribo Price per Unit for 1 Powder Injection of 3.5mg (US$), July’2023
Figure 5-672: Synribo – Cost per Daily Dose, 7 Day Cycle & 28 Day Cycle (US$), July’2023
Figure 5-673: US – Revcovi Price per Unit for 1.5mL Intramuscular Solution of 1.6mg/mL (US$), July’2023
Figure 5-674: US – RiaSTAP Price per Unit for 1 Intravenous Powder Injection (US$), July’2023
Figure 5-675: US – Provigil Price per Unit for 30 Oral Tablets of 100mg & 200mg (US$), July’2023
Figure 5-676: US – Cuvposa Price per Unit for 473mL Oral Solution of 1mg/5mL (US$), July’2023
Figure 5-677: US – BioThrax Retail Price (US$) July’2023
Figure 5-678: US – Qualaquin Price per Unit for 30 Oral Capsules of 324mg (US$), July’2023
Figure 5-679: US – Tindamax Price per Unit for 20 Oral Tablets of 500mg (US$), July’2023
Figure 5-680: US – Zirgan Price per Unit for 5g Ophthalmic Gel of 0.15% (US$), July’2023
Figure 5-681: US – Calcium Acetate Price per Unit for 30, 50, 100 & 200 Oral Capsules of 667mg (US$), July’2023
Figure 5-682: US – Calcium Acetate Price per Unit for 200 Oral Tablets of 667mg (US$), July’2023
Figure 5-683: US – Hemangeol Price per Unit for 120mL Oral Liquid of 4.28mg/mL (US$), July’2023
Figure 5-684: US – AdreView Price per Unit for 1 Intravenous Solution of 370mBq/5mL (US$), July’2023
Figure 5-685: US – Acetadote Price per Unit for 120mL Intravenous Solution of 20% (US$), July’2023
Figure 5-686: US – Riluzole Price per Unit for 60 Oral tablets of 50mg (US$), July’2023
Figure 5-687: US – Totect Price per Unit for 1 Intravenous Powder Injection of 500mg (US$), July’2023
Figure 5-688: Totect – Cost per Daily Dose (US$), July’2023
Figure 5-689: US – Cafcit Price per Unit for 30mL Intravenous Solution of 20mg/mL (US$), July’2023
Figure 5-690: US – Cafcit Price per Unit for 30mL Oral Solution of 20mg/mL (US$), July’2023
Figure 5-691: US – Cafcit Price per Unit for 30mL Oral Solution of 20mg/mL (US$), July’2023
Figure 5-692: US – Diastat Price per Unit for 1 Rectal Kit of 2.5mg (US$), July’2023
Figure 5-693: US – Diastat Price per Unit for 1 Rectal Kit of 2.5mg (US$), July’2023
Figure 5-694: US – Cholbam Price per Unit for 90 Oral Capsules of 50mg & 250mg (US$), July’2023
Figure 5-695: US – Simulect Price per Unit for 1 Powder Injection of 10mg & 20mg (US$), July’2023
Figure 5-696: Simulect – Cost per Recommended Dosage for Adult Patients (US$), July’2023
Figure 5-697: Simulect – Cost per Recommended Dosage for Pediatric Patients (US$), July’2023
Figure 5-698: US – Marinol Price per Unit for 60 Oral Capsules of 2.5mg & 5mg (US$), July’2023
Figure 5-699: US – Biktarvy Price per Unit for 30 Oral Tablets of 30mg, 120mg & 15mg (US$), July’2023
Figure 5-700: US – Biktarvy Price per Unit for 30 Oral Tablets of 50mg, 200mg & 25mg (US$), July’2023
Figure 5-701: US – GONAL-f RFF Price per Unit for 1 & 10 Subcutaneous Powder Injection of alpha 75 IU (US$), July’2023
Figure 5-702: US – Dacogen Price per Unit for 30 1 Powder Injection of 50mg (US$), July’2023
Figure 5-703: US - Revlimid Price per Unit for 28 & 100 Oral Capsules of 2.5mg (US$), July’2023
Figure 5-704: US - Revlimid Price per Unit for 28 & 100 Oral Capsules of 5mg (US$), July’2023
Figure 5-705: US - Revlimid Price per Unit for 28 & 100 Oral Capsules of 10mg (US$), July’2023
Figure 5-706: US - Revlimid Price per Unit for 21 & 100 Oral Capsules of 15mg (US$), July’2023
Figure 5-707: US - Revlimid Price per Unit for 21 & 100 Oral Capsules of 20mg (US$), July’2023
Figure 5-708: US - Revlimid Price per Unit for 21 & 100 Oral Capsules of 25mg (US$), July’2023
Figure 5-709: US – Arikayce Retail Price for28 Vials of 590mg/8.4mL (US$), July’2023
Figure 5-710: US – Amvuttra Price per Unit for 0.5mL Subcutaneous Solution of 25mg (US$), July’2023
Figure 5-711: US – Emflaza Price per Unit for 13mL Oral Suspension of 22.75mg/mL (US$), July’2023
Figure 5-712: US - Gocovri Price per Unit for 60 Oral, Extended Release Capsules of 68.5mg & 137mg (US$), July’2023
Figure 5-713: US – Asparlas Price per Unit for 5mL Intravenous Solution of mknl 750units/mL (US$), July’2023
Figure 5-714: US – Coagadex Price per Unit for 5mL Intravenous 1 Powder Injection (US$), July’2023
Figure 5-715: US – Ampyra Price per Unit for 60 Oral, Extended Tablets of 10mg (US$), July’2023
Figure 5-716: US – Anavip Price per Unit for 1 Intravenous Powder Injection (US$), July’2023
Figure 5-717: US – Durezol Price per Unit for 5mL Ophthalmic Emulsion of 0.05% (US$), July’2023
Figure 5-718: US – Colazal Price per Unit for 280 Oral Capsules of 750mg (US$), July’2023
Figure 5-719: US – Anascorp Price per Unit for 1 Intravenous Powder Injection (US$), July’2023
Figure 5-720: US – Nithiodote Price per Unit for 60mL Intravenous Solution of 30mg- 250mg/mL (US$), July’2023
Figure 5-721: US – BabyBIG Cost per Vial (US$), July’2023
Figure 5-722: US – Sarclisa Price per Unit for 20mg/mL Intravenous Solution of 5mL & 25mL (US$), July’2023
Figure 5-723: Sarclisa – Cost per Dose & Cycle (US$), July’2023
Figure 6-1: Tafinlar - Global Sales (US$ Million), 2019-2023
Figure 6-2: Tafinlar - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-3: Jadenu - Global Sales (US$ Million), 2019-2023
Figure 6-4: Jadenu - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-5: Zolgensma - Global Sales (US$ Million), 2019-2023
Figure 6-6: Zolgensma - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-7: Lynparza - Global Sales (US$ Million), 2019-2023
Figure 6-8: Lynparza - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-9: Nplate - Global Sales (US$ Million), 2019-2023
Figure 6-10: Nplate - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-11: Nplate - US Sales (US$ Million), 2019-2023
Figure 6-12: Nplate - US Sales (US$ Million), Q1-Q4’2022
Figure 6-13: Nplate – Global Sales by Region (US$ Million), 2022
Figure 6-14: Nplate - ROW Sales (US$ Million), 2019-2023
Figure 6-15: Lumakras - Global Sales (US$ Million), 2021-2023
Figure 6-16: Lumakras - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-17: Lumakras - US Sales (US$ Million), 2021-2023
Figure 6-18: Lumakras - US Sales (US$ Million), Q1-Q4’2022
Figure 6-19: Lumakras – Global Sales by Region (US$ Million), 2022
Figure 6-20: Lumakras - ROW Sales (US$ Million), 2021-2023
Figure 6-21: Repatha - Global Sales (US$ Million), 2019-2023
Figure 6-22: Repatha – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-23: Repatha - US Sales (US$ Million), 2019-2023
Figure 6-24: Repatha – US Sales (US$ Million), Q1-Q4’2022
Figure 6-25: Repatha – Global Sales by Region (US$ Million), 2022
Figure 6-26: Repatha - ROW Sales (US$ Million), 2019-2023
Figure 6-27: Otezla - Global Sales (US$ Million), 2021-2023
Figure 6-28: Otezla – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-29: Otezla - US Sales (US$ Million), 2019-2023
Figure 6-30: Otezla – US Sales (US$ Million), Q1-Q4’2022
Figure 6-31: Otezla – Global Sales By Region (US$ Million), 2022
Figure 6-32: Otezla - ROW Sales (US$ Million), 2019-2023
Figure 6-33: Kyprolis - Global Sales (US$ Million), 2019-2023
Figure 6-34: Kyprolis – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-35: Kyprolis - US Sales (US$ Million), 2019-2023
Figure 6-36: Kyprolis – US Sales (US$ Million), Q1-Q4’2022
Figure 6-37: Kyprolis – Global Sales By Region (US$ Million), 2022
Figure 6-38: Kyprolis - ROW Sales (US$ Million), 2019-2023
Figure 6-39: Opdivo - Global Sales (US$ Million), 2019-2023
Figure 6-40: Opdivo – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-41: Opdivo - US Sales (US$ Million), 2019-2023
Figure 6-42: Opdivo – US Sales (US$ Million), Q1-Q4’2022
Figure 6-43: Opdualag - Global Sales (US$ Million), 2022-2023
Figure 6-44: Opdualag – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-45: Opdualag - US Sales (US$ Million), 2022-2023
Figure 6-46: Opdualag – US Sales (US$ Million), Q1-Q4’2022
Figure 6-47: Empliciti - Global Sales (US$ Million), 2019-2023
Figure 6-48: Empliciti – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-49: Empliciti - US Sales (US$ Million), 2019-2023
Figure 6-50: Empliciti – US Sales (US$ Million), Q1-Q4’2022
Figure 6-51: Braftovi - Global Sales (US$ Million), 2019-2023
Figure 6-52: Braftovi – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-53: Braftovi - US Sales (US$ Million), 2019-2023
Figure 6-54: Braftovi – US Sales (US$ Million), Q1-Q4’2022
Figure 6-55: Mektovi - Global Sales (US$ Million), 2019-2023
Figure 6-56: Mektovi – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-57: Mektovi - US Sales (US$ Million), 2019-2023
Figure 6-58: Mektovi – US Sales (US$ Million), Q1-Q4’2022
Figure 6-59: Lorbrena - Global Sales (US$ Million), 2019-2023
Figure 6-60: Lorbrena - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-61: Lorbrena - US Sales (US$ Million), 2019-2023
Figure 6-62: Lorbrena – US Sales (US$ Million), Q1-Q4’2022
Figure 6-63: Besponsa - Global Sales (US$ Million), 2021-2023
Figure 6-64: Besponsa - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-65: Besponsa - US Sales (US$ Million), 2021-2023
Figure 6-66: Besponsa – US Sales (US$ Million), Q1-Q4’2022
Figure 6-67: Besponsa – Global Sales By Region (US$ Million), 2022
Figure 6-68: Besponsa - ROW Sales (US$ Million), 2021-2023
Figure 6-69: Actemra - Global Sales (US$ Million), 2019-2023
Figure 6-70: Actemra - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-71: Actemra - US Sales (US$ Million), 2019-2023
Figure 6-72: Actemra – US Sales (US$ Million), Q1-Q4’2022
Figure 6-73: Tecentriq - Global Sales (US$ Million), 2019-2023
Figure 6-74: Tecentriq - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-75: Tecentriq - US Sales (US$ Million), 2019-2023
Figure 6-76: Tecentriq – US Sales (US$ Million), Q1-Q4’2022
Figure 6-77: Polivy - Global Sales (US$ Million), 2019-2023
Figure 6-78: Polivy - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-79: Polivy - US Sales (US$ Million), 2019-2023
Figure 6-80: Polivy – US Sales (US$ Million), Q1-Q4’2022
Figure 6-81: Luxturna - Global Sales (US$ Million), 2019-2023
Figure 6-82: Luxturna - US Sales (US$ Million), 2019-2023
Figure 6-83: Enspryng - Global Sales (US$ Million), 2020-2023
Figure 6-84: Enspryng - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-85: Enspryng - US Sales (US$ Million), 2020-2023
Figure 6-86: Enspryng – US Sales (US$ Million), Q1-Q4’2022
Figure 6-87: Evrysdi - Global Sales (US$ Million), 2020-2023
Figure 6-88: Evrysdi - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-89: Evrysdi - US Sales (US$ Million), 2020-2023
Figure 6-90: Evrysdi – US Sales (US$ Million), Q1-Q4’2022
Figure 6-91: Kalydeco - Global Sales (US$ Million), 2019-2022
Figure 6-92: Kalydeco - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-93: Trikafta - Global Sales (US$ Million), 2019-2022
Figure 6-94: Trikafta - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-95: Symdeko - Global Sales (US$ Million), 2019-2022
Figure 6-96: Symdeko - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-97: Orkambi - Global Sales (US$ Million), 2019-2022
Figure 6-98: Orkambi - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-99: Reblozyl - Global Sales (US$ Million), 2020-2023
Figure 6-100: Reblozyl - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-101: Reblozyl - US Sales (US$ Million), 2020-2023
Figure 6-102: Reblozyl – US Sales (US$ Million), Q1-Q4’2022
Figure 6-103: Yervoy - Global Sales (US$ Million), 2019-2023
Figure 6-104: Yervoy - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-105: Yervoy - US Sales (US$ Million), 2019-2023
Figure 6-106: Yervoy – US Sales (US$ Million), Q1-Q4’2022
Figure 6-107: Eylea - Global Sales (US$ Million), 2019-2023
Figure 6-108: Eylea - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-109: Eylea - US Sales (US$ Million), 2019-2023
Figure 6-110: Eylea – US Sales (US$ Million), Q1-Q4’2022
Figure 6-111: Evkeeza - Global Sales (US$ Million), 2021-2023
Figure 6-112: Evkeeza - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-113: Evkeeza - US Sales (US$ Million), 2019-2023
Figure 6-114: Evkeeza – US Sales (US$ Million), Q1-Q4’2022
Figure 6-115: Skytrofa - Global Sales (US$ Million), 2022-2023
Figure 6-116: Skytrofa - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-117: Elahere - Global Sales (US$ Million), 2022-2023
Figure 6-118: Jakafi - Global Sales (US$ Million), 2019-2023
Figure 6-119: Jakafi - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-120: Jakafi - US Sales (US$ Million), 2019-2023
Figure 6-121: Jakafi – US Sales (US$ Million), Q1-Q4’2022
Figure 6-122: Ninlaro - Global Sales (US$ Million), 2019-2022
Figure 6-123: Ninlaro - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-124: Ninlaro - US Sales (US$ Million), 2019-2022
Figure 6-125: Ninlaro - US Sales (US$ Million), Q1-Q4’2022
Figure 6-126: Takhzyro - Global Sales (US$ Million), 2019-2022
Figure 6-127: Takhzyro - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-128: Takhzyro - US Sales (US$ Million), 2019-2022
Figure 6-129: Takhzyro - US Sales (US$ Million), Q1-Q4’2022
Figure 6-130: Velcade - Global Sales (US$ Million), 2019-2022
Figure 6-131: Velcade - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-132: Velcade - US Sales (US$ Million), 2019-2022
Figure 6-133: Velcade - US Sales (US$ Million), Q1-Q4’2022
Figure 6-134: Adcetris - Global Sales (US$ Million), 2019-2023
Figure 6-135: Adcetris - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-136: Exkivity - Global Sales (US$ Million), 2021-2023
Figure 6-137: Exkivity - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-138: Exkivity - US Sales (US$ Million), 2022-2023
Figure 6-139: Exkivity - US Sales (US$ Million), Q1-Q4’2022
Figure 6-140: Ocaliva - Global Sales (US$ Million), 2019-2022
Figure 6-141: Ocaliva - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-142: Ocaliva - US Sales (US$ Million), 2019-2022
Figure 6-143: Ocaliva - US Sales (US$ Million), Q1-Q4’2022
Figure 6-144: Onpattro - Global Sales (US$ Million), 2019-2023
Figure 6-145: Onpattro - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-146: Orladeyo - Global Sales (US$ Million), 2022-2023
Figure 6-147: Orladeyo - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-148: Livmarli - Global Sales (US$ Million), 2021-2023
Figure 6-149: Livmarli - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-150: Bendeka - Global Sales (US$ Million), 2019-2023
Figure 6-151: Bendeka - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-152: Firdapse - Global Sales (US$ Million), 2019-2021
Figure 6-153: Firdapse - US Sales (US$ Million), 2019-2021
Figure 6-154: Firdapse - US Sales (US$ Million), Q1-Q4’2022
Figure 6-155: Vyvgart - Global Sales (US$ Million), 2022-2023
Figure 6-156: Vyvgart - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-157: Vyvgart - US Sales (US$ Million), 2022
Figure 6-158: Vyvgart - US Sales (US$ Million), Q1-Q4’2022
Figure 6-159: Tagrisso - Global Sales (US$ Million), 2019-2023
Figure 6-160: Tagrisso - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-161: Tagrisso - US Sales (US$ Million), 2019-2023
Figure 6-162: Tagrisso – US Sales (US$ Million), Q1-Q4’2022
Figure 6-163: Koselugo - Global Sales (US$ Million), 2020-2023
Figure 6-164: Koselugo - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-165: Koselugo - US Sales (US$ Million), 2020-2023
Figure 6-166: Koselugo – US Sales (US$ Million), Q1-Q4’2022
Figure 6-167: Enhertu - Global Sales (US$ Million), 2020-2023
Figure 6-168: Enhertu - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-169: Enhertu - US Sales (US$ Million), 2020-2023
Figure 6-170: Enhertu – US Sales (US$ Million), Q1-Q4’2022
Figure 6-171: Voxzogo - Global Sales (US$ Million), 2020-2023
Figure 6-172: Voxzogo - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-173: Palynziq - Global Sales (US$ Million), 2019-2023
Figure 6-174: Palynziq - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-175: Actimmune – US Sales (US$ Million), 2019-2022
Figure 6-176: Actimmune - US Sales (US$ Million), Q1-Q4’2022
Figure 6-177: Ravicti - Global Sales (US$ Million), 2019-2022
Figure 6-178: Ravicti - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-179: Tecartus - Global Sales (US$ Million), 2020-2023
Figure 6-180: Tecartus - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-181: Tecartus - US Sales (US$ Million), 2020-2023
Figure 6-182: Tecartus – US Sales (US$ Million), Q1-Q4’2022
Figure 6-183: Darzalex - Global Sales (US$ Million), 2019-2023
Figure 6-184: Darzalex - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-185: Darzalex - US Sales (US$ Million), 2019-2023
Figure 6-186: Darzalex – US Sales (US$ Million), Q1-Q4’2022
Figure 6-187: Opsumit - Global Sales (US$ Million), 2019-2023
Figure 6-188: Opsumit - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-189: Opsumit - US Sales (US$ Million), 2019-2023
Figure 6-190: Opsumit – US Sales (US$ Million), Q1-Q4’2022
Figure 6-191: Uptravi - Global Sales (US$ Million), 2019-2023
Figure 6-192: Uptravi - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-193: Uptravi - US Sales (US$ Million), 2019-2023
Figure 6-194: Uptravi – US Sales (US$ Million), Q1-Q4’2022
Figure 6-195: Cyramza - Global Sales (US$ Million), 2019-2023
Figure 6-196: Cyramza - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-197: Cyramza - US Sales (US$ Million), 2019-2023
Figure 6-198: Cyramza - US Sales (US$ Million), Q1-Q4’2022
Figure 6-199: Alimta - Global Sales (US$ Million), 2019-2023
Figure 6-200: Alimta - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-201: Alimta - US Sales (US$ Million), 2019-2023
Figure 6-202: Alimta - US Sales (US$ Million), Q1-Q4’2022
Figure 6-203: Tepezza - Global Sales (US$ Million), 2020-2022
Figure 6-204: Tepezza - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-205: Uplizna - US Sales (US$ Million), 2020-2022
Figure 6-206: Uplizna - US Sales (US$ Million), Q1-Q4’2022
Figure 6-207: Spinraza - Global Sales (US$ Million), 2019-2023
Figure 6-208: Spinraza - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-209: Spinraza - US Sales (US$ Million), 2019-2023
Figure 6-210: Spinraza – US Sales (US$ Million), Q1-Q4’2022
Figure 6-211: Epidiolex - Global Sales (US$ Million), 2020-2023
Figure 6-212: Epidiolex - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-213: Xywav - Global Sales (US$ Million), 2020-2023
Figure 6-214: Xywav - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-215: Xyrem - Global Sales (US$ Billion), 2020-2023
Figure 6-216: Xyrem - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-217: Vyxeos - Global Sales (US$ Million), 2019-2023
Figure 6-218: Vyxeos - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-219: Rylaze - Global Sales (US$ Million), 2021-2023
Figure 6-220: Rylaze - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-221: Pyrukynd - Global Sales (US$ Million), 2022-2023
Figure 6-222: Pyrukynd - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-223: Hemlibra - Global Sales (US$ Million), 2019-2023
Figure 6-224: Hemlibra – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-225: Hemlibra - US Sales (US$ Million), 2019-2023
Figure 6-226: Hemlibra – US Sales (US$ Million), Q1-Q4’2022
Figure 6-227: Prolia - Global Sales (US$ Million), 2019-2023
Figure 6-228: Prolia – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-229: Prolia - US Sales (US$ Million), 2019-2023
Figure 6-230: Prolia – US Sales (US$ Million), Q1-Q4’2022
Figure 6-231: Venclexta - Global Sales (US$ Million), 2019-2023
Figure 6-232: Venclexta – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-233: Venclexta - US Sales (US$ Million), 2019-2023
Figure 6-234: Venclexta – US Sales (US$ Million), Q1-Q4’2022
Figure 6-235: Letairis - Global Sales (US$ Million), 2019-2023
Figure 6-236: Letairis – Global Sales (US$ Million), Q1-Q4’2022
Figure 6-237: Xgeva - Global Sales (US$ Million), 2019-2023
Figure 6-238: Xgeva - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-239: Xgeva - US Sales (US$ Million), 2019-2023
Figure 6-240: Xgeva - US Sales (US$ Million), Q1-Q4’2022
Figure 6-241: Tavneos - Global Sales (US$ Million), 2022-2023
Figure 6-242: Tavneos - Global Sales (US$ Million), Q1-Q4’2022
Figure 6-243: Tavneos - US Sales (US$ Million), 2019-2023
Figure 6-244: Tavneos - US Sales (US$ Million), Q1-Q4’2022
Figure 6-245: COMETRIQ - US Sales (US$ Million), 2019-2022
Figure 6-246: Cabometyx - Global Sales (US$ Million), 2019-2022
Figure 6-247: Cabometyx - US Sales (US$ Million), 2019-2022
Figure 6-248: Carvykti - Global Sales (US$ Million), 2019-2022
Figure 6-249: Carvykti – US Sales (US$ Million), 2019-2022
Figure 6-250: Tabrecta - Global Sales (US$ Million), 2019-2023
Figure 6-251: Tabrecta – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-252: Kymriah - Global Sales (US$ Million), 2019-2023
Figure 6-253: Kymriah – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-254: Onureg - Global Sales (US$ Million), 2020-2023
Figure 6-255: Onureg – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-256: Onureg - US Sales (US$ Million), 2020-2023
Figure 6-257: Onureg – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-258: Pomalyst - Global Sales (US$ Million), 2019-2023
Figure 6-259: Pomalyst – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-260: Pomalyst - US Sales (US$ Million), 2019-2023
Figure 6-261: Pomalyst – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-262: Xiaflex - Global Sales (US$ Million), 2019-2023
Figure 6-263: Recorlev - Global Sales (US$ Million), 2019-2023
Figure 6-264: Recorlev – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-265: Gleevec - Global Sales (US$ Million), 2019-2023
Figure 6-266: Gleevec – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-267: Turalio - Global Sales (US$ Million), 2020-2022
Figure 6-268: Turalio – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-269: Nexavar - Global Sales (US$ Million), 2019-2022
Figure 6-270: Nexavar – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-271: Bosulif - Global Sales (US$ Million), 2019 -2023
Figure 6-272: Bosulif – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-273: Bosulif - US Sales (US$ Million), 2019-2023
Figure 6-274: Bosulif – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-275: Brineura - Global Sales (US$ Million), 2019 -2023
Figure 6-276: Brineura – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-277: Buphenyl - Global Sales (US$ Million), 2019 -2023
Figure 6-278: Buphenyl – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-279: Briviact - Global Sales (US$ Million), 2019 -2022
Figure 6-280: Briviact - US Sales (US$ Million), 2019-2022
Figure 6-281: Botox - Global Sales (US$ Million), 2020-2023
Figure 6-282: Botox – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-283: Botox - US Sales (US$ Million), 2020-2023
Figure 6-284: Botox – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-285: Humira - Global Sales (US$ Million), 2019-2023
Figure 6-286: Humira – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-287: Humira - US Sales (US$ Million), 2019-2023
Figure 6-288: Humira – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-289: Poteligeo - Global Sales (US$ Million), 2019-2022
Figure 6-290: Poteligeo – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-291: Crysvita - Global Sales (US$ Million), 2019-2022
Figure 6-292: Crysvita – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-293: Promacta - Global Sales (US$ Million), 2019-2023
Figure 6-294: Promacta – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-295: Promacta - US Sales (US$ Million), 2019-2023
Figure 6-296: Promacta – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-297: Eloctate - Global Sales (US$ Million), 2019-2023
Figure 6-298: Eloctate – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-299: Eloctate - US Sales (US$ Million), 2019-2023
Figure 6-300: Eloctate – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-301: Xospata - Global Sales (US$ Million), 2019-2022
Figure 6-302: Xospata – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-303: Defitelio - Global Sales (US$ Million), 2019-2023
Figure 6-304: Defitelio – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-305: ReFacto - Global Sales (US$ Million), 2019-2023
Figure 6-306: ReFacto - Global Sales (US$ Million), Q1- Q4’ 2022
Figure 6-307: ReFacto - US Sales (US$ Million), 2019-2023
Figure 6-308: ReFacto – US Sales (US$ Million), Q1- Q4’ 2022
Figure 6-309: Mekinist - Global Sales (US$ Million), 2019-2023
Figure 6-310: Mekinist - Global Sales (US$ Million), Q1- Q4’ 2022
Figure 6-311: Mekinist - US Sales (US$ Million), 2019-2023
Figure 6-312: Mekinist - US Sales (US$ Million), Q1- Q4’ 2022
Figure 6-313: Praluent - Global Sales (US$ Million), 2020-2023
Figure 6-314: Praluent - Global Sales (US$ Million), Q1- Q4’ 2022
Figure 6-315: Praluent - US Sales (US$ Million), 2020-2023
Figure 6-316: Praluent – US Sales (US$ Million), Q1- Q4’ 2022
Figure 6-317: Mozobil - Global Sales (US$ Million), 2019-2023
Figure 6-318: Mozobil - Global Sales (US$ Million), Q1- Q4’ 2022
Figure 6-319: Mozobil - US Sales (US$ Million), 2019-2023
Figure 6-320: Mozobil – US Sales (US$ Million), Q1- Q4’ 2022
Figure 6-321: Yescarta - Global Sales (US$ Million), 2019-2023
Figure 6-322: Yescarta - Global Sales (US$ Million), Q1- Q4’ 2022
Figure 6-323: Yescarta - US Sales (US$ Million), 2019-2023
Figure 6-324: Yescarta – US Sales (US$ Million), Q1- Q4’ 2022
Figure 6-325: Lunsumio - Global Sales (US$ Million), 2022-2023
Figure 6-326: Lunsumio - Global Sales (US$ Million), Q1- Q4’ 2022
Figure 6-327: Lunsumio - US Sales (US$ Million), 2022-2023
Figure 6-328: Keytruda - Global Sales (US$ Million), 2019-2023
Figure 6-329: Keytruda – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-330: Keytruda – US Sales (US$ Million), 2019-2023
Figure 6-331: Keytruda – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-332: Pemazyre - Global Sales (US$ Million), 2019-2023
Figure 6-333: Pemazyre – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-334: Camzyos - Global Sales (US$ Million), 2022-2023
Figure 6-335: Camzyos – Global Sales (US$ Million), Q1 - Q4’ 2022
Figure 6-336: Camzyos - US Sales (US$ Million), 2022-2023
Figure 6-337: Camzyos – US Sales (US$ Million), Q1 - Q4’ 2022
Figure 7-1: US- Number Of Orphan Designated Drugs In Clinical Trials By Company, 2023
Figure 7-2: US- Number Of Orphan Designated Drugs In Clinical Trials By Indication, 2023
Figure 7-3: US- Number Of Orphan Designated Drugs In Clinical Trials By Patient Segment, 2023
Figure 7-4: US- Number Of Orphan Designated Drugs In Clinical Trials By Phase, 2023
Figure 7-5: US- Number Of Orphan Designated Drugs In Clinical Trials By Priority Status, 2023

List Of Tables

LIST OF TABLES

Table 1-1: US – FDA Categorization for Disease or Condition
Table 1-2: US – FDA Criteria for Orphan & non-Orphan Drug Approvals
Table 5-1: Tafinlar – Recommended Weight-Adjusted Dose
Table 5-2: Ocaliva - Dosage Regimen by Disease Stage
Table 5-3: Monjuvi - Dosing Schedule
Table 5-4: Nivolumab – FDA Orphan Drug Designation & Approvals
Table 5-5: Opdivo - Recommended Dosages for Monotherapy
Table 5-6: Opdivo - Recommended Dosages in Combination with Other Therapeutic Agents
Table 5-7: Firdapse -Recommended Oral Dosage for the Treatment of LEMS in Adults & Pediatric Patients 6 Years of Age & Older
Table 5-8: Adult & Pediatric Dosing Regimen by Age & Body Weight
Table 5-9: Recommended Dosage for Hetlioz Capsules and Hetlioz LQ Oral Suspension for Nighttime Sleep Disturbances in SMS
Table 5-10: Ipilimumab – FDA Orphan Drug Designation & Approvals
Table 5-11: Yervoy - Recommended Dosages in Combination with Other Therapeutic Agents
Table 5-12: Bevacizumab - FDA Orphan Drug Designations
Table 5-13: Tpoxx - Recommended Dosage & Preparation Instructions in Pediatric Patients Weighing at Least 13 kg & Adults
Table 5-14: Koselugo - Recommended Dosage Based on BSA
Table 5-15: ACTpen - Recommended Adult Subcutaneous Dosage:
Table 5-16: Actemra - Recommended Dosages for Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Table 5-17: Actemra - Recommended Dosages for Systemic Juvenile Idiopathic Arthritis (SJIA)
Table 5-18: Actemra - Recommended Dosages for Cytokine Release Syndrome (CRS)
Table 5-19: Tecentriq - Recommended Dosage as Single Agent
Table 5-20: Tecentriq - Recommended Dosage in Combination with Other Therapeutic Agents
Table 5-21: Wakix - Recommended Dosage
Table 5-22: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma
Table 5-23: Jakafi - Starting Doses for Myelofibrosis
Table 5-24: Kalydeco - Dosage by Body Weight in Pediatric Patients Ages 6 months to less than 6 Years
Table 5-25: Symdeko - Recommended Dosage for Adult and Pediatric Patients aged 6 Years & Older
Table 5-26: Trikafta - Recommended Dosage for Adult and Pediatric Patients aged 6 Years & Older
Table 5-27: Orkambi - Recommended Oral Dosage of in Patients Aged 1 Year and Older
Table 5-28: Voxzogo - Recommended Daily Dosage and Injection Volume
Table 5-29: Actimmune - Recommended Dosage for the Treatment of Patients with CGD & SMO
Table 5-30: Lisocabtagene maraleucel - FDA Orphan Drug Designation & Approvals
Table 5-31: Tazemetostat - FDA Orphan Drug Designation & Approvals
Table 5-32: Otezla - Dosage Titration Schedule
Table 5-33: Gammagard Liquid - Dosage and Administration
Table 5-34: Fintepla – Recommended Titration Schedule
Table 5-35: Recommended Dosage of Daybue in Patients 2 Years of Age and Older
Table 5-36: Juxtapid - Recommended Regimen for Titrating Dosage
Table 5-37: Myalept - Recommended Dosage
Table 5-38: Empliciti - Recommended Dosing Schedule in Combination with Lenalidomide & Dexamethasone
Table 5-39: Kcentra - Dosage Required for Reversal of VKA Anticoagulation in Patients with acute major bleeding or need for an urgent surgery/invasive procedure
Table 5-40: Sirturo - Recommended Dosage
Table 5-41: Daratumumab – FDA Orphan Drug Designation & Approvals
Table 5-42: Recommended Dose and Duration in Patients with Chronic Liver Disease Scheduled to Undergo a Procedure
Table 5-43: Endari - Recommended Dosing
Table 5-44: Aldesleukin - FDA Orphan Drug Designation & Approvals
Table 5-45: Nulibry - Recommended Dose
Table 5-46: Valtoco - Recommended Dosage for Adults and Pediatric Patients 6 Years of Age and Older
Table 5-47: Vistogard - Recommended Dose
Table 5-48: Xuriden – Recommended Dosage by Body Weight
Table 5-49: Ascor - Recommended Dose & Infusion Rate of Diluted Solution
Table 5-50: BAT Dosing Guide and Intravenous Infusion Rate
Table 5-51: BAT - Pediatric Dosing Guide Based on Salisbury Rule (1 Year to < 17 Years)
Table 5-52: Priftin – Recommended Doses for Patients between the ages of 2 & 11 years
Table 5-53: Gralise - Recommended Titration Schedule
Table 5-54: Pedmark - Recommended Dose
Table 5-55: Palynziq - Recommended Dosing Regimen
Table 5-56: Tembexa - Recommended Dosage
Table 5-57: Rituximab – Orphan Drug Designation & Approvals
Table 5-58: Rituxan – Recommended Dosage
Table 5-59: Cresemba - Recommended Dosage Regimen
Table 5-60: Macitentan - FDA Orphan Drug Designation & Approvals
Table 5-61: Oxlumo - Weight-Based Dosing Regimen
Table 5-62: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma
Table 5-63: Xyrem - Recommended Adult Dose Regimen
Table 5-64: Xyrem - Recommended Pediatric Dosage for Patients 7 Years of Age and Older
Table 5-65: Vyxeos - Dose and Schedule
Table 5-66: Pyrukynd - Dose Titration Schedule
Table 5-67: Oxbryta - Recommended Dosage in Pediatric Patients 4 Years to Less Than 12 Years
Table 5-68: Brentuximab Vedotin – FDA Orphan Drug Designation & Approvals
Table 5-69: Adcetris - Recommended Dosage
Table 5-70: Rebinyn – Dosing for On-demand Treatment and Control of Bleeding Episodes
Table 5-71: Rebinyn - Dosing For Perioperative Management
Table 5-72: Impavido – Recommended Dosage
Table 5-73: Imatinib – FDA Orphan Drug Designation & Approvals
Table 5-74: Eloctate – Dosing for Control of Bleeding Episodes
Table 5-75: Eloctate - Dosing for Perioperative Management
Table 5-76: Rozlytrek – Dosing in Pediatric Patients 12 Years and Older
Table 5-77: Humira – US Orphan Drug Designations
Table 5-78: Humira - Recommended Dosage for Adolescent Patients 12 years of Age & Older Weighing at least 30 kg with Hidradenitis Suppurativa
Table 5-79: Humira - Recommended Dosage for Pediatric Patients 6 Years of Age & Older with Crohn’s Disease
Table 5-80: Humira - Recommended Dosage for Patients 2 Years of Age & Older with Polyarticular Juvenile Idiopathic Arthritis
Table 5-81: Humira - Recommended Dosage for Pediatric Patients 5 Years of Age & Older with Ulcerative Colitis
Table 5-82: Farydak - Recommended Dosing in Combination with Bortezomib and Dexamethasone during Cycles 1 to
Table 5-83: Farydak - Recommended Dosing in Combination with Bortezomib and Dexamethasone During Cycles 9 to
Table 5-84: Serostim - Body Weight-Based Dosage Recommendation
Table 5-85: Obizur - Dosage for On-Demand Management of Bleeding Episodes
Table 5-86: Mekinist – Recommended Dosage & Treatment Cost per Month (30 days) in Pediatric Patients (Weight-Based) (US$), July’2023
Table 5-87: US – Praluent Price per Unit for 2mL of 75mg/mL & 150mg/mL Subcutaneous Solution (US$), July’2023
Table 5-88: Lunsumio – Recommended Dose, Schedule & Cost of Treatment (21-day Treatment Cycle) (US$), July’2023
Table 5-89: Bylvay – Recommended Dosage & Cost per Month (30 Days) for 40mcg/kg/day (US$), July’2023
Table 5-90: Ultomiris – US Orphan Drug Designation History
Table 5-91: Ultomiris – Recommended Loading Dose & Cost per Dose (US$) for 100mg/mL (3mL & 11mL Vials), July’2023
Table 5-92: Ultomiris – Recommended Maintenance Dose & Cost per Dose (US$) for 100mg/mL (3mL & 11mL Vials), July’2023
Table 5-93: HepaGam B – Dosing Regimen for HBV Related Liver Transplant Patients, July’2023
Table 5-94: VariZIG – Recommended Dose, Volume of Administration & Cost per Dose (US$), July’2023
Table 5-95: CytoGam - Recommended Dosage According to Type of Transplant & Cost per Dose (US$), July’2023
Table 5-96: Astagraf XL – Recommended Daily Dosage Regimen & Cost per Dose (US$), July’2023
Table 5-97: Prograf Granules – Recommended Initial Dosage, observed Whole Blood Trough Concentration & Cost per Dose for Pediatric Liver Transplant Patients (US$), July’2023
Table 5-98: Prograf Capsules – Recommended Initial Dosage, Observed Whole Blood Trough Concentration & Cost per Dose for Adult Kidney, Liver or Heart Transplant Patients (US$), June’2023
Table 5-99: Ztalmy – Recommended Titration Schedule for Patients Weighing 28kg or Less, July’2023
Table 5-100: Ztalmy – Recommended Titration Schedule for Patients Weighing More Than 28kg, July’2023
Table 5-101: Venclexta – Recommended Dosing Schedule for RamUp Phase with Cost per Dose for CLL (US$), July’2023
Table 5-102: Venclexta – Recommended Dosing Schedule for RamUp Phase with Cost per Dose for AML (US$), June’2023
Table 5-103: Jynarque – Recommended Daily Dosage per Step & Cost per Dose/Step (US$), July’2023
Table 5-104: US – Jynarque Price per Unit for 56 Oral Tablets of 45mg-15mg (28 Tablets Each) (US$), July’2023
Table 5-105: US – Jynarque Price per Unit for 56 Oral Tablets of 60mg-30mg (28 Tablets Each) (US$), July’2023
Table 5-106: US – Jynarque Price per Unit for 56 Oral Tablets of 90mg-30mg (28 Tablets Each) (US$), July’2023
Table 5-107: US – Jynarque Price per Unit for 30 Oral Tablets of 15mg & 30mg (US$), July’2023
Table 5-108: Corlanor – Recommended Dose Adjustments for Adults, July’2023
Table 5-109: Esbriet – Recommended Dosage Titration, July’2023
Table 5-110: Idelvion – Recommended Dosing for On-Demand Treatment & Control of Bleeding Episodes, July’2023
Table 5-111: Idelvion – Recommended Dosing for Perioperative Management of Bleeding, July’2023
Table 5-112: Mepsevii – Recommended Administration Infusion Rate Schedule by Patient Weight at 4mg/kg, July’2023
Table 5-113: Sabril – Recommended Infant Starting & Maximum Dose, July’2023
Table 5-114: Ixiaro – Recommended Dose, Cycle per Age & Cost per Cycle (US$), July’2023
Table 5-115: Cinryze – Recommended Dosing in Adults, Adolescents & Pediatric Patients, July’2023
Table 5-116: Dysport – Recommended Dosing by Muscle for Lower Limb Spasticity in Pediatric Patients, July’2023
Table 5-117: Xenpozyme – Recommended Dose Escalation Regimen for Adult Patients, July’2023
Table 5-118: Xenpozyme – Recommended Dose Escalation Regimen for Pediatric Patients, July’2023
Table 5-119: Targretin – Initial Dose calculation According to Body Surface Area, July’2023
Table 5-120: Dificid – Recommended Dosage of Oral Suspension in Pediatric Patients, July’2023
Table 5-121: Onfi – Recommended Total Daily Dose by Weight Group, July’2023
Table 5-122: Envarsus RX – Recommended Tacrolimus Whole Blood Trough Concentration Ranges in Kidney Transplant Patients with Antibody Induction, July’2023
Table 5-123: Albenza – Recommended Dosage, July’ 2023
Table 5-124: Ammonul – Recommended Dosage & Administration, July’2023
Table 5-125: Cuvposa - Recommended Dose Titration Schedule (each dose to be given three times daily), July’2023
Table 5-126: BioThrax – Recommended Dose for Pre-Exposure Prophylaxis, July’2023
Table 5-127: BioThrax – Recommended Dose for Post-Exposure Prophylaxis, July’2023
Table 5-128: Hemangeol – Recommended Dose Titration According to Weight
Table 5-129: Acetadote - Three Bag Method Dosage Guide by Weight in Patients 5 kg to 20 kg
Table 5-130: Acetadote - Three Bag Method Dosage Guide by Weight in Patients 21 kg to 40 kg
Table 5-131: Acetadote - Three Bag Method Dosage Guide by Weight in Patients 41 kg to 100 kg
Table 5-132: ATryn – Recommended Dosing Formula for Surgical Patients and Pregnant Women
Table 5-133: ATryn – Recommended AT Activity Monitoring and Dose Adjustment
Table 5-134: Totect – Recommended Dose & Maximum Daily Dose
Table 5-135: Cafcit – Recommended Loading Dose & Maintenance Dose, July’2023
Table 5-136: Corifact – Recommended Dose Adjustment Using the Berichrom Activity Assay
Table 5-137: Diastat – Recommended Dosage per Age (Years), July’2023
Table 5-138: Diastat – Recommended Dose (mg) per Weight kg) & Age (Years), July’2023
Table 5-139: Cholbam – Recommended Number of Cholbam Capsules Needed to Achieve a Recommended Dosage of 10 mg/kg/day, July’2023
Table 5-140: Cholbam – Recommended Number of Cholbam Capsules Needed to Achieve a Recommended Dosage of 15 mg/kg/day, July’2023
Table 5-141: Coagadex – Recommended Dose for Prophylaxis of Bleeding Episodes, July’2023
Table 5-142: Coagadex – Recommended Dose for On–Demand Treatment & Control of Bleeding Episodes, July’2023
Table 5-143: Coagadex – Recommended Dose for Peri-Operative Management of Bleeding, July’2023
Table 5-144: Anavip – Recommended Dosage & Administration, July’2023
Table 5-145: Anascorp – Recommended Dosage & Administration, July’2023
Table 5-146: Nithiodote – Recommended Age Specific Dosing, July’2023
Table 5-147: Sarclisa – Dosing Schedule in Combination with Pomalidomide & Dexamethasone, July’2023